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The aim of this doctoral thesis was 
to evaluate the possibility to utilize 
transporters present at the blood-brain 
barrier for enhanced brain uptake of 
drugs. The study is divided into three 
parts. In the first two parts, the ability 
of LAT1 to transport amino acid pro-
drugs across the blood-brain barrier 
is evaluated. The third part describes 
the evaluation GluT1 mediated brain 
uptake of glucose prodrugs.   
Mikko Gynther
Blood-Brain Barrier 
Transporters in 
CNS Drug Deliery
Design and Biological Evaluation of LAT1
and GluT1 –Targeted Prodrugs
Mikko Gynther
Blood-Brain Barrier Transporters 
in CNS Drug Delivery
Design and Biological Evaluation of LAT1 and 
GluT1 –Targeted Prodrugs
MIKKO GYNTHER
Blood-Brain Barrier
Transporters in CNS Drug
Delivery:
Design and Biological Evaluation of LAT1 and GluT1
–Targeted Prodrugs
To be presented by permission of the Faculty of Health Sciences,
University of Eastern Finland for public examination
in auditorium ML3, Medistudia building, University of Eastern Finland, Kuopio,
on Saturday 9th of October 2010, at 12 noon.
Publications of the University of Eastern Finland
Dissertations in Health Sciences
29
School of Pharmacy
Faculty of Health Sciences
University of Eastern Finland
Kuopio
2010
II
Kopijyvä Oy
Kuopio, 2010
Series Editors:
Professor Veli-Matti Kosma, MD, PhD
Department of Pathology
Institute of Clinical Medicine
School of Medicine
Faculty of Health Sciences
Professor Hannele Turunen, PhD
Department of Nursing Sciences
Faculty of Health Sciences
Distribution:
Eastern Finland University Library/Sales of Publications
P.O.Box 1627, FI-70211 Kuopio, FINLAND
http://www.uef.fi/kirjasto
ISBN 978-952-61-0212-2
ISBN 978-952-61-0213-9 (PDF)
ISSN 1798-5706
ISSN 1798-5714 (PDF)
ISSNL 1798-5706
III
Authors address: School of Pharmacy
Faculty of Health Sciences
University of Eastern Finland
P.O.Box 1627,
FI-70211 Kuopio, Finland
mikko.gynther@uef.fi
Supervisors: Professor Jarkko Rautio, PhD
School of Pharmacy
Faculty of Health Sciences
University of Eastern Finland
Kuopio, Finland
Krista Laine, PhD
School of Pharmacy
Faculty of Health Sciences
University of Eastern Finland
Kuopio, Finland
Jarmo Ropponen, PhD
VTT Technical Research Centre of Finland
Espoo, Finland
Reviewers: Professor Marjo Yliperttula, PhD
Faculty of Pharmacy
Division of Biopharmaceutics and Pharmacokinetics
University of Helsinki
Helsinki, Finland
Professor Peter Swaan, PhD
School of Pharmacy
Department of Pharmaceutical Sciences
University of Maryland
Baltimore, USA
Opponent: Jouni Sirviö, PhD
Oy Sauloner Ltd
Kuopio, Finland
IV
VGynther, Mikko. Blood-Brain Barrier Transporters in CNS Drug Delivery:
Design and Biological Evaluation of LAT1 and GluT1 –Targeted Prodrugs.
Publications of the University of Eastern Finland. Dissertations in Health
Sciences 29. 2010. 129 p.
ABSTRACT
The underlying reason for under-penetrated global central nervous system
(CNS) drug market is the lack of efficient delivery strategies that enable drugs
to circumvent the blood-brain barrier (BBB). Several specific endogenous
influx transporters have been identified at the brain capillary endothelium
forming the BBB. The aim of the study was to design and synthesize amino
acid and glucose prodrugs of ketoprofen and indomethacin and to evaluate
their ability to cross the BBB via transporters.
In the present study we were able to demonstrate that ketoprofen-tyrosine and
ketoprofen-lysine amide prodrugs are able to cross the BBB carrier-
mediatedly. In addition, ketoprofen-lysine amide prodrug was taken up by
brain cells in vivo, where ketoprofen was released.
In the case of glucose prodrugs the results strongly suggest, that a hydrophilic
drug  can  be  attached  to  D-glucose  and  still  maintain  the  affinity  glucose
transporter. However, glucose as a promoiety has several limitations. The
stability of ester prodrugs in systemic circulation might not be adequate for
clinical use of ester prodrugs for drug brain targeting.
In conclusion, both LAT1 and GluT1 are able to deliver prodrugs across the rat
BBB and the parent drug is released in the brain parenchyma. However, more
effort  has  to  be  done  before  this  prodrug  approach  is  fully  applicable  for
clinical use. Glucose prodrugs are too labile and therefore are not useful to
enhance brain uptake. Amino acid prodrugs are more interesting, because
there  are  more  options  which  bond is  used  between the  parent  drug  and the
promoiety. The application of amino acid prodrugs for enhanced brain drug
delivery might be limited to small molecular weight drugs with extremely low
or non-existent brain uptake.
National Library of Medicine Classification: QV 785, WL 200, QV 76.5, WL 300, QU 55.2,
QU 120
Medical Subject Headings: Drug Delivery Systems; Central Nervous System; Prodrugs;
Blood-Brain Barrier; Membrane Transport Proteins; Carrier Proteins; Large Neutral
Amino Acid Transporter 1; Glucose Transporter Type 1; Ketoprofen; Indomethacin
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TIIVISTELMÄ
Yksi tärkeä syy useiden keskushermostosairauksien heikolle vasteelle
lääkehoitoon on lääkeaineiden riittämätön pääsy vaikutuspaikkaansa. Tämä
johtuu veri-aivoesteestä, joka suojaa tehokkaasti aivojen homeostaasia.
Tässä tutkimuksessa selvitettiin voidaanko aihiolääkkeitä hyödyntää
keskushermostokohdentamisessa. Aihiolääkkeet ovat lääkeaineen inaktiivisia
johdoksia, jotka vapauttavat lääkeaineen ennen imeytymistä, imeytymisen
jälkeen tai tietyssä kohdekudoksessa. Näin voidaan vaikuttaa lääkeaineen
kulkeutumiseen elimistössä ilman että vaikutetaan sen kykyyn saada aikaan
haluttu lääkevaste. Lääkeaineisiin liitettiin biologisesti hajoavilla sidoksella
erilaisia aihio-osia. Tavoitteena oli selvittää voivatko kuljetusproteiinit
kuljettaa keskushermostoon muodostetun aihiolääkkeen.
Aihiolääkkeiden kyky hyödyntää kuljetusproteiineja tutkittiin eläinkokeiden
avulla. Veriaivoesteen läpäisyn lisäksi on tärkeää selvittää kuinka suuri osuus
aihiolääkkeestä ja lääkeaineesta on sitoutunut epäspesifisesti aivokudokseen.
Molekyylien jakautuminen aivoissa määritettiin yhdistämällä eläinkokeiden ja
aivohomogenaateissa tehtyjen in vitro -kokeiden avulla.
Väitöskirjatyössä saavutettujen tulosten perusteella voidaan todeta että
aihiolääkkeitä voidaan hyödyntää keskushermostokohdentamiseen
kuljetusproteiinien avulla. Lisäksi tutkimuksessa pystyttiin osoittamaan, että
aihio-osalla voidaan vaikuttaa lääkeaineen jakautumiseen aivojen
solunsisäisen ja solunulkoisen nesteen välillä. Tutkimustuloksia voidaan
hyödyntää pyrittäessä edistämään erittäin huonosti keskushermostoon
kulkeutuvien lääkeaineiden pääsyä vaikutuspaikkaansa.
Yleinen suomalainen asiasanasto: lääkeaineet; aihiolääkkeet; keskushermosto;
kohdentaminen
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1 Introduction
Due to the aging of the general population, the burden of central
nervous system (CNS) diseases continues to increase (Pardridge,
2003). It has been estimated by WHO and the World Bank that
in  the  21st  century  the  costs  associated  with  CNS  disorders  in
Europe will be over one third of the total disease burden (Olesen
et al., 2006). In addition, it has been estimated that one out of
every three individuals will experience a CNS condition during
their lifetime.
Recent advances in biotechnology and pharmaceutical sciences
have greatly expanded the number of drugs that are being
developed for the treatment of CNS disorders. Drugs identified
through novel discovery techniques often do not consider the
pharmacokinetic and pharmaceutical properties of the drug
candidates. The reasons for the under-penetrated CNS drug
market is the lack of efficient delivery strategies that enable
drugs to circumvent the blood-brain barrier (BBB) and poor
knowledge which molecular properties and pharmacokinetical
parameters should be optimized (Pardridge, 2003; Jeffrey and
Summerfield, 2007). The BBB represents an efficient structural
and functional barrier for the delivery of therapeutic agents into
the CNS. Due to its unique properties, passage across the BBB
often becomes the main limiting factor for the delivery of
potential CNS drugs into the brain parenchyma. In fact, it has
been estimated that more than 98% of small-molecular weight
drugs developed for the CNS diseases do not readily cross the
BBB (Pardridge, 2005a).
The BBB endothelial cells differ from endothelial cells in the rest
of the body by the presence of tight junctions, lack of fenestrae
and the low frequency of pinocytic vesicles (Rubin and Staddon,
1999). There are also numerous enzymes and efflux-proteins
present at the cerebral endothelial cells (Cordon-Cardo et al.,
1989; Anderson, 1996). Due to these distinctive features of the
2BBB, it exhibits an efficient barrier for the penetration of drugs
into  CNS.   However,  as  each  neuron  in  the  human  brain  is
perfused  by  its  own  blood  vessel,  a  solute  that  is  able  to  cross
the  BBB  is  distributed  rapidly  into  the  whole  brain  tissue
(Pardridge, 2002a). Therefore, it is essential to develop new
strategies to circumvent the BBB. The primary route of drug
uptake into cells has been considered to be passive diffusion
through the lipid bilayer of the cellular membrane. Recently it
was reported that there is significant evidence supporting the
view that drug uptake is, in fact, mainly transporter mediated
(Dobson and Kell, 2008). Specific endogenous influx
transporters have been identified at the brain capillary
endothelium, the cells forming the BBB. These include large
neutral amino acid transporter (LAT1) and glucose transporter
type 1 (GluT1) (Pardridge and Oldendorf, 1977). The new
awareness of these endogenous BBB transporters can be used in
the rational modification of drug molecules for carrier-mediated
transport (Rautio et al., 2008). In the view of the successful
introduction of L-dopa over three decades ago, it is surprising
that utilization of BBB transporters has not been more widely
exploited in overcoming the barriers to CNS penetration.
However, the complexity of this approach is often
underappreciated, since it requires a sophisticated knowledge of
CNS anatomy and physiology, as well as complex chemistry if it
is to be successful.
The main objective of the present study was to prove that LAT1
and GluT1, which are both present at the BBB, can be utilized
for  brain  drug  delivery  by  conjugating  drugs  with  endogenous
substrates or substrate analogs of the transporters. It was
hypothesized that by exploiting transporters the BBB
permeation properties of drugs could be improved without
increasing the non-specific tissue binding into the brain.
However, good in vitro or in situ BBB permeability of drug
molecules does not itself guarantee adequate brain uptake in
vivo. Therefore, the second objective of the study was to prove
that the nutrient promoieties are able to affect the systemic
3pharmacokinetics of the drug molecules and increase the brain
uptake in vivo.
2 Review of the literature
2.1 GENERAL BACKGROUND OF CENTRAL NERVOUS SYSTEM
DRUG DELIVERY
The CNS includes the brain and the spinal cord. There are three
barriers that limit drug transport into the brain (de Boer and
Gaillard, 2007). These are the BBB, the blood-cerebrospinal fluid
barrier (BCSFB), and the ependyma. The most important influx
barrier preventing solutes from entering the brain is the BBB.
The BBB is localized in the capillaries of the brain. The human
BBB has an estimated surface area of approximately 20 m2 (Keep
and Jones, 1990). BCSFB attributable to the choroid plexus
epithelium in the ventricles and the surface area is
approximately the same as the surface area of the BBB.
However, a large surface area of the BCSFB faces the cerebral
spinal fluid (CSF), not blood, and therefore, the BCSFB is not as
important influx barrier for CNS drugs as the BBB. Ependyma is
an epithelial layer of cells covering the brain tissue in the
ventricles and it limits the transport of compounds from CSF to
the brain tissue (Bruni, 1998).
The  delivery  of  drugs  into  the  CNS  is  difficult  to  achieve
although brain is highly perfused by capillaries and every cubic
centimeter of cortex contains 1 km of blood vessels (de Boer and
Gaillard, 2007). The entry of molecules from blood to brain is
efficiently governed by the BBB and only small lipophilic
molecules are able to cross the BBB by passive diffusion. It has
been estimated that more than 98% of all potential new CNS
drugs do not readily cross the BBB in sufficient amounts to have
the desired pharmacological effect (Pardridge, 2003) (Fig. 2.1). In
addition  to  brain  tissue  being  a  hard  to  reach  for  drugs,  it  has
4been far from obvious what parameters should be used to
determine adequate brain uptake of drugs (Jeffrey and
Summerfield, 2007; Hammarlund-Udenaes et al., 2008). The
brain to plasma concentration ratio (Kp) has been the most
widely used parameter to evaluate and optimize the brain
uptake during the drug discovery process (Liu et al., 2008). The
current optimization paradigm, where better brain penetration
has been viewed as increasing Kp of the drugs, may be incorrect,
since higher Kp ratios are often a consequence of increased non-
specific binding to brain tissue. In recent publications, the
unbound brain to plasma concentration ratio (Kp,free or Kp,uu) has
been suggested to be a more important parameter in brain
uptake optimization than Kp (Hammarlund-Udenaes et al., 2008;
Liu et al., 2008). In addition, as drug efficacy is ultimately
characterized by the relationship between the effect and drug
concentration in the target tissue, the benefits of brain to blood
concentration ratio optimization may be marginal in CNS drug
discovery (de Lange, 2005; Jeffrey and Summerfield, 2007).
The global CNS drug market is highly under-penetrated. It has
been estimated that one out of every three individuals will
suffer a CNS condition during their lifetime, which means that
the market of CNS drugs should be the largest sector in the
pharmaceutical industry (Regier et al., 1988). However, the
global CNS pharmaceutical market would have to grow more
than 500% simply to match the share of the market occupied by
cardiovascular drugs (Pardridge, 2002b).
The most challenging CNS diseases for drug treatment are
neurodegenerative diseases, characterized by age-related
gradual decline in neurological function (Pardridge, 2002b).
These are for example, Alzheimer's disease, Parkinson's disease
and Huntington's disease. Non-neurodegenerative diseases are
often easier to treat and respond to small molecular weight drug
treatments (Pardridge, 2005a). In addition, these CNS diseases
are often not age-related. Examples of CNS diseases that
respond to small molecular weight drugs are affective disorders,
chronic pain, migraine and epilepsy.
5The underlying reason for under-penetrated CNS drug market
is the lack of efficient delivery strategies that enable drugs to
circumvent the BBB. New knowledge on the structure and
function of the BBB and the parameters describing brain uptake
have provided an opportunity for the development of new
strategies to overcome the CNS delivery problem. However,
these new CNS targeting strategies have to be integrated into
the drug design process at a very early stage. One promising
strategy, which is also utilized in the present thesis are
prodrugs. Prodrugs are compounds that undergo a chemical or
enzymatic biotransformation prior to their therapeutic activity
(Rautio et al., 2008). Release of the active drug is controlled and
can occur before, during or after absorption, or at the specific
site of  action within the body, depending upon the purpose for
which the prodrug is designed (Stella et al., 1985).
Figure 2.1. A schematic illustration of CNS drug discovery
process. Virtually all drugs developed from receptor-based high
throughput–screening programs for CNS drug discovery are
either water soluble with a high degree of hydrogen bonding or
CNS drug
discovery
Trial and error
Rational drug
design
(high throughput
screening)
BBB transport of
drug is negligible
CNS drug
delivery
CNS drug
development
Program
termination
6have a molecular weight greater than 400–500 Da. Without a
rational CNS targeting strategy implemented in the drug
discovery process, the drug design program is often terminated,
because of poor brain uptake. Modified from (Pardridge, 2001b).
2.2 STRUCTURE AND FUNCTION OF THE BLOOD-BRAIN
BARRIER
The BBB is essential for all animals with a complex CNS since it
prevents the free movement of materials between the blood and
the brain (Fig. 2.2). The BBB regulates the movement of solutes
from blood to brain and it buffers the brain interstitial fluid from
fluctuations in composition that occur in plasma (Braun et al.,
1980; Begley, 2004b). In addition, the low permeability of the
BBB to most neurotransmitters allows separation of the CNS
and peripheral nervous system transmitter pools. Since it
controls the movement of molecules from blood to brain, the
BBB allows the precise regulation of solute concentrations in the
interstitial fluid, which is essential for the propriate function of
the CNS. The BBB is  present in all  brain regions,  except for the
circumventricular organs, where blood vessels have
fenestrations that permit diffusion of solutes from blood to brain
across the vessel wall (Ballabh et al., 2004). The unprotected
areas of the brain regulate autonomic nervous system and
endocrine glands of the body. The diffusion barrier of the BBB is
due to endothelial cells with their continuous tight junctions
(Pardridge, 2007b). In addition, the cells surrounding brain
capillaries, such as astrocytes, pericytes, perivascular microglia
and neurons contribute to the formation and maintenance of a
functional BBB in the CNS (Goldstein, 1988; Dohgu et al., 2005;
Nakagawa et al., 2007). Since the BBB blocks the passive
diffusion of hydrophilic molecules, the efflux of hydrophilic
metabolites formed in the CNS and the influx of hydrophilic
nutrients are restricted. Therefore, there are several endogenous
transporter mechanisms present at the BBB, which can facilitate
the movement of both hydrophilic and large molecules across
7the BBB (Pardridge, 1999a; Tsuji and Tamai, 1999; de Boer and
Gaillard, 2007; Pardridge, 2007c). There is also high enzymatic
activity in the cells forming the BBB, which can efficiently
metabolize bioactive molecules before they cross the BBB and
gain access to the brain parenchyma (Pardridge, 2005b).
Figure 2.2. The structure of the blood-brain barrier.
Endothelial cells
The BBB is formed by a continuous layer of endothelial cells
which form a very thin but very effective barrier between blood
and brain parenchyma. Since the distance between luminal and
abluminal membranes of endothelial cells is only 200 nm, this
allows substances to cross the endothelial cells and enter the
brain parenchyma within a short time (Stewart et al., 1985;
Pardridge, 2005a). The brain capillary endothelial cells differ
from the endothelial cells in the rest of the body, by having very
little of pinocytotic and transsytotic activity and by their large
number of mitochondria, suggesting their high energy
metabolism (Oldendorf et al., 1977; Engelhardt, 2003).
Transcytosis  of  molecules  across  the  BBB  is  an  adenosine
8triphosphate (ATP) -dependent transport process and this
enhanced energy potential may be related to energy-dependent
transport across the BBB. The basement membrane of the BBB
endothelial cells is common with that of the perivascular
astrocytic endfeet and that of the pericytes, which are
completely surrounded by a basement membrane, making the
endothelial cells tightly integrated to the brain parenchyma (Allt
and Lawrenson, 2001; Ballabh et al., 2004; Wolburg et al., 2009).
The luminal surface of cerebral endothelial cells carries a
negative charge due to negatively charged proteoglycans,
glycosaminoglycans, glycoproteins and glycolipids on the
surface of the cells (Fatehi et al., 1987; Brightman and Kaya, 2000;
Begley and Brightman, 2003). This 25 nm thick glycocalyx
covering the endothelial cells is a major resistance barrier to the
passage of small solutes (Brightman and Kaya, 2000). In
addition, cerebral endothelial cells express a wide spectrum of
enzymes such as γ-glutamyl transpeptidase, alkaline
phosphatase, butyrylcholine esterase, and aromatic acid
decarboxylase, thus creating an enzymatic barrier between
blood and brain (Betz et al., 1980; Anderson, 1996; Pardridge,
2005b). Furthermore, BBB endothelial cells express several
transporter proteins, including P-glycoprotein (P-gp) (Cordon-
Cardo et al., 1989; Thiebaut et al., 1989), multidrug resistance-
associated proteins (MRPs) (Borst et al., 2000), GluT1 (Farrell
and Pardridge, 1991), LAT1 (Boado et al., 1999; Duelli et al.,
2000), the monocarboxylic acid transporter 1 (MCT1) (Gerhart et
al., 1997), cationic amino acid transporter (y+) (O'Kane et al.,
2006) and the adenosine transporter (CNT2) (Li et al., 2001).
Tight junctions
The most important factors responsible for the restriction of the
paracellular diffusion across the BBB are the junctional
complexes which arwe present between the endothelial cells
(McCaffrey et al., 2007). Tight junctions encircle the endothelial
cells and the membranes of adjacent endothelial cells are
completely fused. Therefore, the tight junctions between
9adjacent endothelial cells are 50–100 times tighter than those
encountered in peripheral endothelium (Abbott, 2002). In
addition to sealing the paracellular route across the BBB, tight
junctions are responsible for the polarization of the endothelial
cells, which is manifested by a non-uniform distribution of
transporters between the luminal and abluminal membranes
(McCaffrey et al., 2007). Tight junctions are large, multiprotein
complexes and the structure of the tight junction in the BBB has
been found to be the most complex of all such entities in the
entire vasculature of the body (Forster, 2008). The molecular
components of tight junctions can be divided into different
classes based on their structures and functions, including
integral membrane proteins and cytoplasmic accessory proteins
(Ballabh et al., 2004; Wolburg et al., 2009). Cytoplasmic proteins
link membrane proteins to actin, which is the primary
cytoskeleton protein involved in the maintenance of structural
and functional integrity of the endothelium.
Astrocytes
Astrocytes encircle 90-99% of the capillaries formed by the
endothelial cells (Pardridge, 2005a). In addition, astrocytes are
attached to a basement membrane shared with the endothelial
cells (Ballabh et al., 2004). However, the endfoot processes are
not sealed to each other and the small gaps between the
astrocytes allow passage of large and hydrophilic molecules.
Although astrocytes do not take part in the formation of the
physical barrier of the BBB, they are important in the
development and maintenance of the BBB (Wolburg et al., 2009).
Astrocytes induce and modulate the development of the BBB
and its unique endothelial cell phenotype. In vitro studies have
demonstrated, that astrocyte - endothelial cell interactions
enhance endothelial cell tight junctions and reduce gap
junctional area (Tao-Cheng et al., 1987; Tao-Cheng and
Brightman, 1988; Wolburg et al., 1994). It has been reported that
astrocytes are important for the expression of several
transporter proteins in the brain endothelial cells, such as LAT1,
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GluT1 and P-gp (El Hafny et al., 1997; Hayashi et al., 1997;
Omidi et al., 2008). Moreover, the expression of several enzymes
at the BBB is induced by astrocytes (Beck et al., 1986; Tontsch
and Bauer, 1991). Therefore, astrocytes can play a major role in
the BBB metabolism.
Pericytes
Pericytes are undifferentiated, contractile connective tissue cells
that develop around capillary walls and share the basal
membrane with brain capillary endothelial cells (Allt and
Lawrenson, 2001; Persidsky et al., 2006). In addition, gap
junction communication between pericyte and endothelial cells
has been demonstrated in vitro (Larson et al., 1987; Lai and Kuo,
2005). Furthermore, pericytes are essential in structural
differentiation of the brain endothelial cells, and formation of
endothelial tight junctions (Nakagawa et al., 2007). Cerebral
pericytes express several enzymes, such as γ-glutamyl
transpeptidase and glutamyl aminopeptidase, therefore
constituting a major component of the metabolic BBB (Frey et al.,
1991; Song et al., 1993). In addition, it has been suggested that
cerebral pericytes have phagocytotic potency (Jordan and
Thomas, 1988).
2.3 MECHANISMS AFFECTING THE BRAIN UPTAKE OF DRUGS
The BBB represents an efficient barrier for the brain uptake of
neuropharmaceuticals (Fig. 2.3). In addition to the optimal
physicochemical properties, adequate brain uptake also requires
that the drugs cannot be substrates of efflux proteins that are
expressed on the luminal membrane of the endothelial cells.
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Figure 2.3. Mechanisms of brain uptake.
2.3.1 Passive diffusion
Passive  diffusion  across  the  BBB  is  believed  to  be  the  most
common  mechanism  of  CNS  drug  brain  uptake.  Although  the
importance of transporter mediated brain uptake may be
underestimated. Passive diffusion involves an energy
independent movement of drug molecules along a
concentration gradient, and the rate of diffusion is directly
proportional to the concentration gradient of the solutes across
the membrane. Passive diffusion can occur either between the
cells (paracellular) or through the cells (transcellular),
depending on the physicochemical properties of the solutes.
Since tight junctions block the paracellular route across the BBB,
only solutes which are able to penetrate through the endothelial
cell  membrane  are  able  to  cross  the  BBB  via  passive  diffusion.
Therefore, only a few drug molecules are able to efficiently cross
the BBB by passive diffusion. It has been suggested that the BBB
permeation by passive diffusion is restricted to those molecules
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which possess the criteria listed in Table 2.1. Examination of a
comprehensive medicinal chemistry database revealed that the
average molecular weight of the CNS active drug is 357 Da
(Ghose et al., 1999). In a more recent study it was reported that
the mean molecular weight of 74 CNS-drugs launched between
years 1983-2002 was 310 Da (Leeson and Davis, 2004). This
supports the limit for molecular weight presented in Table 2.1.
Table 2.1. The criteria for passive permeation of drugs across
the BBB.
Properties                    Limita CNS drugs b
average min max
Molecular weight <450 298 129 654
(Da)
Hydrogen bond <3 1.03 0 4
donors
Hydrogen bond <7 3.33 1 9
acceptors
CLogP <5 2.55 -2.38 5.79
Polar surface area <90 45.98 3.24 115.54
(Å2)
a according to (Pajouhesh and Lenz, 2005)
b CNS drugs marketed in Finland according to Pharmaca Fennica 2010. The
properties of the drugs were calculated with ChemBio3D Ultra 12.0.
The average properties of CNS-drugs marketed in Finland fit
well in the limits presented in Table 2.1. There are few
exceptions in every category of properties and out of 129 drugs
13 molecules do not fulfill all the properties in Table 2.1. The
mechanism of brain uptake of these drugs may be other than
passive diffusion. For example, L-dopa, which has PSA of 103.78
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Å2, utilizes LAT1 for brain uptake (Gomes and Soares-da-Silva,
1999b). Another Parkinson`s disease drug bromocriptine has
molecular weight of 654.53 Da and PSA of 114.45 Å2 and is still
able to cross the BBB, although the mechanism of brain uptake is
unknown. Three drugs with sulfonamide functional group,
sulpiride, sulthiame and topiramate, have PSA over the limit
presented in the Table 2.1 and the passive diffusion across the
BBB may be limited. In fact, sulpiride has been reported to be
substrate of organic cation transporter 2 (OCTN2) in Caco-2 cell
line (Watanabe et al., 2002). OCTN2 has been reported to be
present at the BBB, and may mediate the brain uptake of
sulpiride, sulthiame and Topiramate (Friedrich et al., 2003;
Inano et al., 2003).
Although small lipophilic molecules are able to cross the BBB by
passive diffusion, those molecules may encounter other
limitations. Lipophilic drugs are often highly bound to brain
tissue (Summerfield et al., 2007). The non-specific binding of the
drugs to the brain tissue enlarges the distribution volume of the
drugs  in  the  brain  parenchyma,  which  sustains  the  blood  to
brain concentration gradient and enhances brain uptake (Liu et
al., 2005; Summerfield et al., 2007). However, as only the free
fraction of the drug is effective, the high brain uptake due to the
non-specific  brain  tissue  binding  is  futile.  In  recent  years,  drug
development has focused on optimizing the drug-target protein
interactions, which has lead to the development of large
molecules, which do not fulfill the requirements for passive BBB
permeation (Pardridge, 2003). Furthermore, only a few of the
drugs that are active in the CNS have been developed for
illnesses other than affective disorders, because only a few brain
diseases consistently respond to lipid-soluble small molecules
(Ajay et al., 1999; Ghose et al., 1999; Lipinski, 2000). Therefore, it
can be postulated that brain uptake mechanisms other than
passive  diffusion  may  become  more  significant  in  CNS  drug
development in the future.
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2.3.2 Carrier-mediated transport
The many transporter processes present in the cerebral
endothelial cells enable the movement of hydrophilic and large
molecules across the BBB (Tsuji and Tamai, 1999; Pardridge,
2007c). Carrier-mediated transporter proteins move small
hydrophilic  molecules  such  as  amino  acids  and  glucose.  Some
transporters are unidirectional in their transport of solutes
across the cell membrane and move solutes either from brain to
blood or from blood to brain. Some transporters are
bidirectional, and therefore, transport of some solutes can be
facilitated in either direction depending on whether the
concentration gradient across the BBB is directed into or out of
the CNS (Meier et al., 2002; Begley, 2004a; Tsuji, 2005).
Carrier-mediated transporters can be divided into active
transporters and equilibrative transporters. Active transporters
are either primary or secondary active. Primary active
transporters have intracellular ATP binding sites whereas
secondary active transporters require the presence of an ion
gradient to facilitate the transport of molecules (O'Kane et al.,
2004; Dallas et al., 2006). Equilibrative transporters do not
require energy. However, unlike active transporters the
equilibrative transporters are not able to move solutes against a
concentration gradient. The function of carrier-mediated
transporters is temperature dependent and their activity can be
influenced with competitive or non-competitive inhibitors
(Blodgett and Carruthers, 2005). Moreover, carrier-mediated
transporters can be saturated and their uptake follows
Michaelis-Menten kinetics. The BBB transporters are expressed
on the luminar and/or abluminal membranes of the endothelial
cells depending on the transporter. It has been suggested that
carrier-mediated transporters are able to move molecules which
have a molecular mass below 600 Da (Pardridge, 2001a).
However, the actual limit of the molecular mass may vary
depending on the transporter. Carrier-mediated transporters
facilitate the uptake of various essential nutrients into the CNS,
including amino acids, glucose, vitamins and nucleosides
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(Pardridge and Oldendorf, 1977; Boado et al., 1999; Chishty et al.,
2004; Cornford and Hyman, 2005; Park and Sinko, 2005), since
their brain supply would be restricted without the presence of
the transporters in the endothelial cells (Table 2.2). As many
drug molecules have similar structural properties to
endogenous substrates, it is clear that some membrane
transporters can participate in drug transport (Tamai and Tsuji,
2000). Two carrier-mediated transporters, GluT1 and LAT1, will
be discussed in more detail, since these transporters are
considered as the most promising transporters to be utilized for
brain drug delivery with prodrug technology (Walker, 1994;
Halmos et al., 1996; Bonina et al., 1999; Bonina et al., 2003;
Fernandez et al., 2003).
LAT1
LAT1 has an important role in the maintenance of the normal
function of the mammalian brain, because the rates of amino
acid incorporation into brain proteins by means of cerebral
protein synthesis are about the same as the rates of amino acid
influx across the BBB (Pardridge, 1998). In addition, the surface
area of the brain cell membranes is significantly greater than the
surface area of the BBB (Lund-Andersen, 1979). Therefore, the
LAT1-mediated amino acid transport across the BBB is the rate-
limiting step in amino acid movement from blood to brain
intracellular spaces (Boado et al., 1999). LAT1 transfers one
amino  acid  out  of  the  cell  while  another  amino  acid  is
transported into the cell (Verrey, 2003). The driving force of
LAT1  is  provided  by  a  Na+-dependent amino acid transporter
that carries an amino acid that is a common substrate for both
systems. However, the dynamics of the whole system are not yet
fully  understood.  LAT1  is  only  able  to  modify  the  relative
concentrations of different substrate amino acids, and cannot
induce a change in the overall intracellular amino acid
concentration. Therefore, the net direction of the transport of
amino acids is believed to depend on the unidirectional Na+-
dependent transporters that are co-expressed in the cells. Since
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LAT1 is expressed in parallel to the unidirectional transporters
at the BBB, LAT1 can participate in the flux of amino acids from
the blood to the brain or, under certain circumstances, from the
brain to the blood (Sanchez del Pino et al., 1995; Ennis et al.,
1998). LAT1 is expressed on the luminal and abluminal
membranes of brain capillary endothelial cells (Verrey, 2003). In
addition, LAT1 is also expressed in testis, placenta and tumours
(Kanai et al., 1998; Yanagida et al., 2001). This suggests that
LAT1 is involved mainly in the transport of amino acids into
growing cells and across some endothelial and epithelial
barriers.  The  amount  of  LAT1 mRNA in  bovine  brain  capillary
endothelial cells determined with Northern blotting
experiments is approximately 100-fold greater compared to
other tissues, such as lung, spleen, testis, and heart (Boado et al.,
1999). In addition, the level of LAT1 mRNA was higher relative
to GluT1 mRNA at the BBB. However, the higher level of
mRNA may not correlate with a higher level of LAT1 compared
to GluT1, since the maximum transport velocity (Vmax) of GluT1
is significantly higher than the Vmax of LAT1 (Pardridge, 2001b).
However, the abundant LAT1 mRNA at the BBB may mean that
this transcript has a high turnover rate (Boado et al., 1999). It has
been proposed that one regulation mechanism of LAT1 gene
expression at the BBB may be posttranscriptional and that the
regulation of BBB LAT1 gene expression may play an important
role in the adaptive response of the brain to an abnormal plasma
amino acid supply.
The affinity of large neutral amino acids for LAT1 at the BBB is
much higher than the affinity of amino acids for the other L-
system transporters in peripheral tissues (Boado et al., 1999). In
humans the Michaelis constant (Km) for LAT1 at the BBB is 10-
100 µM, whereas the Km for peripheral amino acid transporters
is 1-10 mM. In addition, the Km of LAT1 at the BBB is similar to
the plasma concentration of circulating large amino acids, which
means that this transporter is saturated under normal conditions
(Pardridge, 1986). LAT1 preferentially transports large neutral
amino acids such as leucine, isoleucine, valine, phenylalanine,
tyrosine and histidine (Boado et al., 1999; Duelli et al., 2000). An
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analysis of the structures of the LAT1 substrates revealed that
LAT1 substrates need to possess an amino group, carboxyl
group and hydrophobic side chain in order to be recognized by
LAT1 (Fig. 2.5) (Uchino et al., 2002). Results from affinity tests
suggest that by removing either the amino group or the carboxyl
group of leucine and phenylalanine, the affinity for LAT1 is lost.
However, by conjugating LAT1 substrate from the side chain to
a drug molecule, the affinity can be sustained. This information
can be utilized for rational design of drugs and prodrugs that
are then able to penetrate the BBB via the LAT1. In addition,
since LAT1 expression is up-regulated in rapidly dividing
tumor cells in order to supply these cells with essential amino
acids to meet their need for continuous growth and proliferation,
it may be possible to impair the growth of tumors by inhibiting
LAT1 activity (Langen et al., 2001).
Figure 2.5. A simplified illustration of LAT1 binding site
(Uchino et al., 2002; Smith, 2005). The illustration is heavily
simplified. However, because of lack of crystal structure for
LAT1 the simplified model serves as a good template for drug
and prodrug design when the aim is to utilize LAT1.
GluT1
GluT1 transports D-glucose, which is the main energy source of
brain, across the BBB and then further into the neuronal cells
(Mueckler, 1994). It has been estimated that the glucose
consumption  of  the  human  brain  is  30%  of  the  entire  body
glucose consumption, and the brain endothelium transports
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about  ten  times  its  weight  in  glucose  per  minute  (Dick  et  al.,
1984; LaManna and Harik, 1985). GluT1 mediates energy
independent transport of glucose, which leads to glucose
equilibration, but not glucose accumulation, by cells. Moreover,
GluT1 is a bi-directional transporter, and the presence of
intracellular and/or extracellular glucose alters the kinetics of
transport both in and out of the cell (de Graaf et al., 2001; Qutub
and Hunt, 2005; Simpson et al., 2007). The density of glucose
transporters in the BBB endothelium is three to four times
higher in the abluminal than in the luminal membrane (Farrell
and Pardridge, 1991). There are two types of glucose
transporters, namely sodium -dependent and -independent
transporters (Nishizaki et al., 1995; Wright et al., 1997; de Graaf
et al., 2001). Sodium-independent glucose transporters are
thought to be functional in the brain, although some studies
claim that sodium-dependent glucose transporters may also be
present in the brain (Nishizaki et al., 1995). Two different
molecular weight forms (45 and 55 kDa) of GluT1, due to
different extents of glycosylation, have been detected in
mammalian brain (Birnbaum et al., 1986). However, their
protein structure or kinetic characteristics are similar. The Vmax
of GluT1 is 1420 nmol/min × g tissue and the transporter
capacity is estimated to be 15‒3000 -fold higher than that for
other transporters present at the BBB, such as MCT1 and LAT1
(Pardridge, 1983). Due to the high capacity of GluT1 at the BBB,
it is expected to be applicable for the brain delivery of drugs
(Pardridge, 1983). Furthermore, there are current data which can
be used to create a model for the exofacial configuration of
GluT1 in which transmembrane segments form an inner helical
bundle that comprises a water-accessible cavity within the
membrane (Fig. 2.6) (Mueckler and Makepeace, 2008). This
knowledge of the glucose binding site allows the rational design
of glucose analogs as well as prodrugs, which can utilize GluT1
for enhanced BBB permeation. In addition, as GluT1 ensures the
insatiable glucose consumption of some cancer cell types, it
could  be  useful  to  inhibit  the  function  of  GluT1  in  these  cells
(Amann et al., 2009; Ganapathy et al., 2009).
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Figure 2.6. A  proposed  and  simplified  model  of  the  exofacial
glucose-binding site of GluT1. Dotted lines represent the
hydrogen bonds between the transporter and glucose (Mueckler
and Makepeace, 2008). This simplified model of the binding site
can  be  used  for  glucose  prodrug,  because  it  shows  which
hydroxyl groups are important for the substrate binding.
2.3.3 Receptor-mediated transport
Brain uptake of large molecules such as peptides and proteins is
limited due to the BBB. The endocytotic activity of BBB
endothelial cells is lower than in the peripheral endothelial cells
(Rubin and Staddon, 1999). However, the brain uptake of some
large molecular weight molecules is necessary to ensure the
normal function of the brain. Therefore, some peptides and
proteins gain their access into the CNS via receptor-mediated
transport or nonspecific absorbtive mediated transcytosis (Fig.
2.3)  (Begley,  2004b).  Brain  influx  of  nutrients,  such  as  iron,
insulin and leptin is mediated by transferrin receptor, insulin
receptor, and leptin receptor, respectively (Jefferies et al., 1984;
Hydrogen bond
acceptor
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Duffy and Pardridge, 1987; Golden et al., 1997). Transcytosis
occurs when circulating ligand interacts with a specific receptor
at the luminal membrane of the endothelial cell (Brown and
Greene, 1991). In receptor-mediated endocytosis, the uptake of
particles or ligands is saturable because it is dependent upon the
extracellular availability of receptors (Mellman, 1996; de Boer,
2003). This receptor-ligand binding then induces an endocytic
event in the luminal membrane that probably involves
aggregation of receptor-ligand complexes and triggers the
internalization of an endocytotic vesicle containing the receptors
and the attached protein molecules. This process requires
energy and is also temperature sensitive. In addition, the
internalization process is time dependent. These internalized
vesicles can then enter a pathway, which carries them across the
endothelial cell during which the peptide/protein is dissociated
from the receptor and exocytosed at the luminal membrane of
the endothelial cell, resulting in transport across the BBB (Begley,
2004b). In this way, molecules can cross the endothelium and
enter the brain without disruption of the barrier properties.
While receptor-mediated transport systems are selective
pathways for trans-BBB transport in that they require the initial
binding of a ligand to some moiety on or in the plasma
membrane of the endothelial cells that make up the BBB,
nonspecific absorbtive mediated transcytosis relies on
nonspecific charge-based interactions (Bickel et al., 2001).
Nonspecific absorbtive mediated transcytosis can be initiated by
polycationic molecules binding to negative charges on the
plasma membrane (Pardridge et al., 1990). In contrast to carriers,
receptors are able to internalize relatively large compounds and
systems and are therefore more suited for targeted drug
delivery of peptides, proteins, and even nanoparticles to the
brain (Munn, 2001).
Receptor-associated protein (RAP) is found mainly in the
endoplasmic reticulum (Pan et al., 2004). RAP plays a key role in
the proper folding and trafficking of members of the low-
density lipoprotein receptor family within the secretory
pathway, including low-density lipoprotein receptor-related
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protein 1 (LRP1) and low-density lipoprotein receptor-related
protein 2 (LRP2) (Bu et al., 1995). There are two main
consequences to the existence of RAP transport across the BBB.
First, the transport system could be enhanced to facilitate the
transport of ligands such as RAP and its homologous proteins.
An alternative approach is the use of a transport system with a
ligand as a carrier protein. Therefore, it may be possible to
attach the target drug to RAP to provide efficient transport into
the brain. It was reported by (Pan et al., 2004) that RAP crosses
the BBB by an efficient, saturable transport system probably
mediated by megalin. In this process, RAP enters the brain
parenchyma intact. Identification of a specific transport system
for RAP at the BBB has highlighted the potential for RAP-
mediated delivery of therapeutic peptides and proteins from
blood to brain.
The principle of using BBB transport mechanisms can be also
applied to large peptides and proteins that may use either
receptor-mediated transcytosis or non-specific absorbtive
mediated transcytosis (Begley, 2004b). Receptor-mediated
transytosis -mediated drug delivery also takes advantage of the
endogenous BBB-transport systems, and aims to improve brain
uptake by coupling non-transportable therapeutic molecules to
a drug-transport vector (Pardridge, 1999b; Bickel et al., 2001). A
drug-transport vector may include endogenous peptides, such
as insulin or transferrin, a modified protein, or it may include
anti-receptor specific monoclonal antibodies (MAb) that
undergo transcytosis through the BBB via the endogenous
receptor system within the brain capillary endothelium.
Conjugation of a drug to a transport vector can be facilitated
either by chemical linkers, avidin-biotin technology,
polyethylene glycol linkers, or liposomes. The MAb binds an
exofacial epitope on the receptor that is spatially removed from
the binding site of the endogenous ligand and this receptor
binding  allows  the  MAb  to  piggy  back  across  the  BBB  via  the
endogenous receptor-mediated transytosis system within the
BBB.  The  receptor-specific  MAb  may  act  as  a  molecular  Trojan
horse  and  ferry  any  attached  drug  or  non-viral  plasmid  DNA
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across the BBB. By employing a MAb to the receptor as the
vector rather than the substrate protein itself, the strategy avoids
the endogenous substrate in blood competing for receptors at
the BBB (Bickel et al., 1994). The capacity of this system for
delivery is generally quite low, as the use of a vector in this
manner results in only one molecule of peptide/protein being
delivered per transferrin receptor antibody (Begley, 2004b).
2.3.4 Active efflux transport
Active efflux transporters have a major impact on the drug
systemic pharmacokinetics in the body (Fromm, 2000; Loscher
and Potschka, 2005). The transcellular brain uptake of some
small  lipophilic  solutes is  not as high as would be indicated by
their lipophilicity (Levin, 1980; Kusuhara and Sugiyama, 2001).
The lower brain uptake of lipophilic solutes is often due to
active efflux proteins, such as P-gp, that remove solutes from
endothelial cells (Loscher and Potschka, 2005). The impact of
efflux proteins on the brain uptake of CNS drugs is significant,
because the efflux transporters have a broad range of substrates,
and strong substrates of BBB efflux transporters do not pass the
BBB to a functionally relevant extent, which restricts their
therapeutic effects to the periphery. Although, active efflux
transporters are very important factor in pharmacokinetics they
are  not  discussed  in  more  detail,  because  the  scope  of  the
present thesis is on the utilization of the influx transporters.
2.4 PARAMETERS AND METHODS USED TO STUDY AND
ESTIMATE BRAIN PERMEATION OF DRUGS
2.4.1 Parameters describing drug uptake across the blood-
brain barrier in animal models
Brain penetration kinetics can be described by the extent and
time to reach brain equilibrium (Liu and Chen, 2005;
Hammarlund-Udenaes et al., 2008). The lack of success in brain
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drug delivery to date might be due to a lack of any consensus
about regarding which processes and properties are most
relevant to successful brain drug delivery. A combination of
measurements has been proposed, as a single rapid method
cannot map all the important factors. In the past, the
optimization of Kp has been used as the parameter that describes
best the extent of brain drug delivery in animal studies (Liu et
al., 2008). However, several studies have shown that the
optimization of Kp leads to non-specific brain tissue binding and
the usefulness of this parameter has been criticized (Pardridge,
2004; Jeffrey and Summerfield, 2007; Summerfield et al., 2007).
As it is generally accepted that it is the unbound drug that exerts
the pharmacological effects, the extent should be defined as
Kp,free at steady state (Hammarlund-Udenaes et al., 1997;
Syvanen et al., 2006; Hammarlund-Udenaes et al., 2008; Liu et al.,
2008). In addition, the distribution of the free drug inside the
brain compartments is crucial (Fig. 2.7). The comparative
importance of unbound drug concentrations in different brain
compartments, extracellular fluid (ECF) or intracellular fluid
(ICF), depends on where the site of action is situated. If the drug
in question is actively transported across the cell membrane,
brain ICF concentrations could be expected to differ from brain
ECF concentrations (Friden et al., 2007; Hammarlund-Udenaes
et al., 2008). There is no direct method for measuring the
concentration ratio between ICF and ECF (Kp,free,cell). However,
recently  an  indirect  technique  was  proposed,  where  by
combining data from in vitro rat  brain slice method with in vivo
rat brain concentration the drug ICF concentration can be
calculated (Friden et al., 2007). Furthermore, the
pharmacological effects of CNS drugs are characterized by the
relationship between efficacy and the drug concentrations at the
active site (de Lange, 2005; Jeffrey and Summerfield, 2007).
Therefore, the optimization of the partition ratio between
plasma and brain is less important than the optimization of the
absolute concentrations at the active site.
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Figure 2.7. A schematic illustration of brain compartments
(Hammarlund-Udenaes et al., 2008).
For  some CNS drugs,  the  time  to  reach  brain  equilibrium is  as
important a parameter as the extent of brain permeation (Liu et
al., 2005). Rapid brain penetration can be achieved by increasing
BBB permeability and reducing brain tissue binding. Thereby
the unbound drug concentration at the target site in brain tissue
can reach equilibrium with the plasma unbound concentration
rapidly after administration. The property of rapid brain
penetration can be gauged by the time to reach brain
equilibrium. Therefore, a short time to achieve brain equilibrium
is a surrogate for a rapid achievement of active brain
concentration. The rate of transport of a drug across the BBB is
estimated as the PA product, or the influx clearance (Kin) which
are clearance measurements and not rates per se (Equation 1)
(Hammarlund-Udenaes et al., 2008).
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ܭ௜௡ = ௤೟೚೟ ష ೇೡ × ಴೛೑் × ஼೛೑ (1)
where qtot is total brain concentration, Vv is the vascular volume
of the brain, Cpf is the perfusion fluid concentration and T is the
perfusion time. The transformation of Kin to  the  PA product  is
performed using the Crone-Renkin model (Equation 2) (Killian
et al., 2007).
ܲܣ = −ܨ × ݈݊[1 − (ܭ௜௡/ܨ)] (2)
where F is the flow rate determined with lipophilic solute such
as diazepam used as a marker for cerebral blood flow.
The time to achieve brain equilibrium can be quantitated with
intrinsic brain equilibrium half-life (t1/2eq.in), a parameter
proposed by Equation 3 (Liu et al., 2005).
ݐଵ/ଶ ୀ ೇ್ ೗೙మ
ುಲ × ೑ೠ,್ೝೌ೔೙ (3)
where Vb is the physiological volume of brain and fu,brain is the
free fraction of the drug in brain tissue.
The distribution of drugs into other tissues than brain decreases
the plasma concentration, and therefore might increase the Kp or
Kp,free, although the brain uptake of the drug is actually
decreased (Pardridge, 2003). Therefore, sometimes the
optimization of Kp,free can lead to decreased brain concentrations
of drugs. The percent of injected dose of a drug that is delivered
per gram brain (%ID/g) should be determined for CNS drugs,
because %ID/g determines how large fraction of the drug dose is
delivered into the brain instead of determining the distribution
ratio between brain and blood. %ID/g is directly proportional to
both the BBB PA product and the area under the plasma
concentration curve (AUC) (Equation 4).
26
% ூ஽
௚
= ܲܣ × ܣܷܥ (4)
The fraction of unbound drug in the brain originates from the
perception that drug distribution within the brain is largely
dominated by non-specific binding, which can be determined by
a brain homogenate binding technique (Kalvass and Maurer,
2002; Maurer et al., 2005; Friden et al., 2007). The parameter
fu,brain is therefore the fraction of unbound drug in (undiluted)
brain homogenate. The in vivo interpretation of actual unbound
drug concentrations in ECF is difficult since the intact brain has
distinct compartments i.e., the intra- and extracellular spaces. It
cannot be directly assumed that the concentration of unbound
drug in brain ECF equals that in brain ICF, as there are also
transporters in the brain parenchymal membranes (Thurlow et
al., 1996; Dallas et al., 2006). It is currently not possible to
directly measure intracellular unbound drug concentrations, but
indirect techniques are emerging from the combined use of rat
brain slice uptake experiments and binding studies in
homogenised brain (Friden et al., 2007). Due to the absence of
plasma  proteins  in  the  brain  ECF  and  the  small  fraction  of
membrane surface area that faces the ECF, drug binding in brain
tissue can be considered as intracellular (Friden et al., 2007). By
combining the brain homogenate binding techniques of
intracellular binding with measures from brain slice uptake
method, Kp,free,cell can be calculated.
   A previously described approach to account for the effect of
tissue dilution on unbound fraction was used to calculate the
brain unbound fraction (Equation 5) (Kalvass and Maurer, 2002).
௨݂,௕௥௔௜௡ = ௙ೠ,೓೚೘೚೒೐೙ೌ೟೐஽ି(஽ିଵ)௙ೠ,೓೚೘೚೒೐೙ೌ೟೐ (5)
where D represents the -fold dilution of brain tissue, and fu,
homogenate is the ratio of concentrations determined from the buffer
and brain homogenate samples.
27
The  unbound  drug  volume  of  distribution  in  the  brain  (Vu,brain)
describes the relationship between the total drug concentration
in  the  brain  and the  unbound drug  concentration  in  brain  ECF
(Equation 6) (Hammarlund-Udenaes et al., 2008). Vu,brain is
measured in mL/g brain:
௨ܸ,௕௥௔௜௡ = ஺௎஼್ೝೌ೔೙஺௎஼ೠ,್ೝೌ೔೙ ಶ಴ಷ (6)
where AUCbrain (nmol/g brain ×  min)  comprises  the  amount  of
unbound drug in the ECF and the amount of drug associated
with the cells (Equation 7):
ܣܷܥ௕௥௔௜௡ = ௕ܸ௥௔௜௡ா஼ி  × ܣܷܥ௨,௕௥௔௜௡ா஼ி + ௖ܸ௘௟௟ × ܣܷܥ௖௘௟௟ (7)
VbrainECF and  Vcell are the physiological fractional volumes of the
brain ECF and brain cells, respectively (mL/g brain), and AUCcell is
the amount of drug associated with the cells (nmol/mLcell × min).
The distribution volume of unbound drug in the cell is
described  by  Vu,cell (mLICF/mLcell) and the intracellular
concentration  of  unbound  drug  is  described  by  AUCu,cell
(nmol/mLICF × min) (Equation 8):
ܣܷܥ௖௘௟௟ =  ௨ܸ,௖௘௟௟  × ܣܷܥ௨,௖௘௟௟  (8)
Vu,cell, describes the affinity of the drug for physical binding
inside the cells (Friden et al., 2007), and it was estimated using
the brain homogenate binding experiment and taking Vcell into
account in the dilution factor (Equation 9):
௨ܸ,௖௘௟௟ = 1 + ஽௏௖௘௟௟ ( ଵ௙ೠ,೓ವ − 1) (9)
When combining Vu,cell assayed from homogenate binding
method  and  Vu,brain acquired from in vivo microdialysis and in
vivo whole tissue experiments or by using in vitro brain slice
method, the ICF-to-ECF concentration ratio of unbound drug
can be calculated as follows (Equation 10):
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ܭ௣,௙௥௘௘,௖௘௟௟ = ஼ೠ,೎೐೗೗஼ೠ,್ೝೌ೔೙ಶ಴ಷ = ௏ೠ,್ೝೌ೔೙ି௏್ೝೌ೔೙ಶ಴ಷ௏೎೐೗೗× ௏ೠ,೎೐೗೗  (10)
2.4.2 In vitro methods
Generally in vitro methods offer some advantages over in vivo
methods. These include a lower compound requirement, greater
throughput, ability to assess mechanisms involved in the uptake
process separately, the identification of early signs of cell
toxicity, and finally lower cost (Lundquist and Renftel, 2002). In
addition, the use of in vitro methods can decrease the use of
laboratory animals, and more importantly reduce painful
operations performed on animals, and therefore is ethical. In
vitro methods for brain uptake studies can be divided into two
groups: 1) in vitro methods that aim to accurately replicate the
conditions involved in in vivo brain uptake, and 2) methods that
are used to study separately the processes determining the brain
uptake (Lasbennes and Gayet, 1984; Joo, 1993) (Gumbleton and
Audus, 2001; Jeffrey and Summerfield, 2007).
The in vitro BBB models which aim to replicate in vivo conditions
include isolated brain capillaries, primary and low passage
brain capillary endothelial cell cultures, immortalized brain
endothelial cells and immortalized artificial membranes
(Lundquist and Renftel, 2002). An ideal in vitro model should
have similar paracellular permeability and transporter
characteristics as the in vivo human BBB and should be easily set
up for routine drug screening (Liu et al., 2008). More research is
needed to develop such an in vitro BBB model. To overcome the
limitations of these cultured cells, extensive studies are being
conducted to develop better in vitro BBB models using either
primary animal brain endothelial cells or immortalized brain
endothelial cells. Coculture with astrocytes has been used to
mimic the in vivo environment (Li et al., 2010). To an attempt to
better mimic in vivo situation,  a  dynamic  coculture  model  in  a
hollow-fiber cartridge has been developed (Neuhaus et al.,
2006). However, because of the complicated set up and low
throughput of this dynamic model, it is difficult to use in drug
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discovery in its current format. The major advantage with
isolated brain capillaries is their close resemblance to the in vivo
situation and they have indeed proved to be suitable for the
detailed studying of the molecular interactions underlying
several important endothelial functions. However, their major
drawbacks from an industrial perspective are that they are not
well suited for screening purposes. An immortalized cell line
has the advantage of being less labour intensive (Cucullo et al.,
2008). However, there are several disadvantages e.g. cells have
been manipulated they form incomplete tight junctions and lack
the necessary paracellular barrier properties in order to be
considered as a BBB permeability screen (Rist et al., 1997).
Transport studies reported with immortalized cell lines also
have mainly been concerned with drug uptake in the cells rather
than transendothelial drug transport. Madin-Darby canine
kidney cells (MDCK) cells show low permeability to sucrose and
this, in combination with the ease with which MDCK cells can
be grown, have led to their proposed use as a BBB screen for
passively transported CNS compounds (Lundquist and Renftel,
2002). There are also MDCK cells available, transfected with the
human multi-drug resistance -1 gene leading to a polarized
overexpression of P-gp, which has proved to be an important
BBB efflux mechanism. However, the noncerebral cells are
morphologically very different from brain endothelial cells and
also differ with respect to transport properties, metabolism and
growth. The morphological differences compared to cerebral
endothelial cells are likely to be reflected in drug–cell membrane
interactions resulting not only in different transport-mediated
permeation but also transfer mediated by passive diffusion.
From the academic research point of view, it is not interesting to
screen vast amounts of molecules. Instead, it is more important
to study the processes that influence the brain uptake of drugs,
and in vitro methods are suitable for this research. Three major
factors have been suggested to determine the brain uptake of
drugs (Jeffrey and Summerfield, 2007). These are passive
membrane permeability, facilitated drug transport and the
relative degree of tissue binding between blood and brain. These
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processes act in concert and the determination of which of these
processes dictate the extent of brain uptake is difficult in vivo.
Therefore, in vitro methods are important for brain uptake
research, because these three processes can be individually
studied one at a time (Jeffrey and Summerfield, 2007). Several in
vitro cell culture models have been developed for the means to
study membrane permeation of potential CNS drug molecules
(Di et al., 2009). In passive membrane permeation studies, it is
important that the cell model does not express membrane
transporters or enzymes involved on the drug metabolism
(Jeffrey and Summerfield, 2007). In addition, tight junctions
between the cells should be present, because they are a
significant part of the in vivo BBB morphology.
If one wishes to determine the significance of transporter
mediated efflux or influx, the cell model should express specific
transporters. The rat brain endothelial cell line (RBE4) is
probably the most extensively characterized cell line in which
the endothelial cells have been transfected with a plasmid
containing the E1A adenovirus gene. The RBE4 has been shown
to functionally express a number of BBB transporters (Begley et
al., 1996; Reichel et al., 2000). In addition to studying carrier-
mediated uptake across continuous cell layers, the interactions
between transporters and drug molecules and also carrier-
mediated cellular uptake can be studied with cell suspensions
such as freshly isolated human erythrocytes, which express
GluT1 (Halmos et al., 1996; Fernandez et al., 2003). Furthermore,
several transporters have been transfected and expressed in
Xenopus laevis oocytes and used for transporter research (Uchino
et al., 2002; Boado et al., 2005).
In vitro brain tissue binding technique in homogenized rat brain
is based on an assumption that drug binding in brain tissue can
be considered as being intracellular (Friden et al., 2007).
Accordingly, the brain homogenate binding method measures
intracellular binding and this allows the distribution volume of
the free drug in the intracellular compartment to be estimated.
When Vu,free,cell is combined with distribution volume of free drug
in the brain calculated from in vivo brain microdialysis and
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whole brain tissue or from brain slice method, the Kp,free,cell can be
calculated.
2.4.3 In situ rat brain perfusion technique
The primary objective of in situ rat brain perfusion technique is
to substitute for the blood circulation of the brain via direct
infusion of perfusion medium into the major vessels leading to
the brain, such as carotid arteries (Fig. 2.8) (Takasato et al.,
1984). A known concentration of the solute of interest is infused
into the brain at a desired infusion flow rate and time. After the
perfusion, the amount of solute in the brain is determined and
appropriate transport or permeability constants are calculated.
A number of variations of the in situ brain perfusion technique
have been published and some of the complexity of the method
has been removed over the time (Foster and Roberts, 2000;
Smith and Allen, 2003). The experimental conditions can be
easily manipulated to study saturable processes such as carrier-
mediated uptake, and moreover, experimental conditions that
would  be  toxic  in  the in vivo situation  can  be  used.  The  most
important advantage over in vivo experiments is the simplicity
of the pharmacokinetics permitting an accurate determination of
the uptake mechanism possible (Smith and Allen, 2003;
Summerfield et al., 2007). In vivo techniques take into account
not only BBB penetration but also binding to plasma proteins,
metabolism, and clearance. There is significant value in
removing some of this complexity and assessing brain
penetration at the level of the BBB in situ. The most important
advantage over in vitro techniques is that the BBB is in its
normal physiological state when the in situ technique is used.
In situ brain perfusion technique can be used to determine the
mechanism of uptake of drugs. In addition, pharmacokinetic
parameters such as Vmax and  Km can be determined for carrier-
mediated uptake. This is possible because the composition of the
perfusion medium can be easily manipulated in terms of drug
and/or transporter inhibitor concentration. Furthermore, the
parameters describing the permeability of a drug across the
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BBB, such as PA product or Kin, can be determined. In addition,
by combining the PA product data acquired from in situ studies
with in vitro unbound fraction in brain tissue,  the time to reach
brain equilibrium can be evaluated for CNS drugs (Liu et al.,
2005). However, the estimation of the extent of the in vivo brain
uptake is problematic, because systemic pharmacokinetics
cannot be determined with in situ brain perfusion.
Figure 2.8. A schematic illustration of in situ rat brain perfusion
technique modified from (Foster and Roberts, 2000). Perfusion
medium is pumped into the brain capillaries through the
common carotid artery.
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2.4.4 In vivo methods
In vivo brain uptake studies can be divided into two approaches:
the single pass uptake approach and the continuous uptake
approach (Smith, 1989). The techniques using the single pass
approach include the indicator diffusion technique and the brain
uptake index technique and the single injection-external
registration technique. The most commonly used continuous
uptake approach is the intravenous administration technique. In
the intravenous administration technique, the drug is injected
intravenously as a bolus injection or as a constant infusion. The
time range in which the samples are drawn from blood can
range from 10 seconds to several hours, and at the end brain is
removed for sampling. The intravenous technique remains the
reference for other brain uptake studies because it represents
fully physiological conditions. Moreover, it offers the possibility
to measure tissue uptake over long periods of time. In addition,
information on systemic pharmacokinetics of a compound may
be gained simultaneously (Bickel, 2005). This is considered as
one of the main advantages of this technique. In addition, the
possibility to evaluate the pharmacokinetics of drugs in steady
state adds the value of the intravenous injection method.
However, there are potential pitfalls which should be noted in
order to avoid erroneous evaluation and data interpretation.
Especially with metabolically labile substances, specific
analytical methods to measure the intact fraction in blood and
tissue have to be developed. Furthermore, unless there is
irreversible binding of the test substance in brain tissue, the
movement across the BBB is bidirectional at sufficiently late
time points. Moreover, the interpretation of the results can be
difficult because of the complexity of the peripheral
pharmacokinetics. Therefore, it can be problematic to evaluate
some individual process involved in the brain uptake. In
addition, when drug concentrations are determined from whole
brain tissue, the unbound concentration of the drug in the brain
parenchyma cannot be evaluated. Finally only one time point
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can be determined from one experiment leading to sacrifice of
many animals before sufficient data can be gathered.
Brain microdialysis
Intracerebral microdialysis involves direct sampling of brain
ECF by implanting a dialysis probe into the brain. The
microdialysis probe consists of a semipermeable membrane and
is perfused with a physiological solution, whereby compounds
that are small enough to traverse the semipermeable membrane
diffuse from higher to lower concentration according to
concentration gradient (Fig. 2.9) (de Lange et al., 1999). The
concentration of compound that has permeated into the brain
following oral, intravenous or subcutaneous administration can
be monitored over time within the same animal. Therefore, one
of the major advantages compared to whole brain concentration
determination is that microdialysis provides pharmacokinetic
profiles of compounds in the brain without the need to sacrifice
many  animals  at  different  time  points.  In  addition,  with
microdialysis, the free concentration in the ECF is measured,
which is pharmacologically the more important fraction of the
concentration than the non-specifically bound fraction (de
Lange and Danhof, 2002). However, it cannot always be
concluded that the ECF and ICF concentrations are equal.
Therefore, when the site of action is located to be intracellular,
the microdialysis and whole brain tissue data should be
combined in order to evaluate the free ICF drug concentration
(de Lange and Danhof, 2002). One major disadvantage of the
microdialysis technique is that if one is not interested in
localized concentrations, this raises the issue of where to place
the probe and whether multiple probes should be used in order
to optain an appropriate representation of drug levels
throughout the brain (Bonate, 1995). The other major
disadvantage associated with intracerebral microdialysis is that
insertion of the probe can result in chronic BBB disruption
(Westergren et al., 1995). In addition, valid quantitative
interpretation of microdialysis data requires the individual
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calibration of the probes to obtain correction factors, which
relate the dialysate concentration to the brain ECF
concentration. However, drug extraction across the probe
membrane measured in vitro is generally greater than that
occurring in vivo. Even though in vitro calibration of the probes
is considered sufficient, in vivo recovery may still deviate from
in vitro recovery (de Lange et al., 1999).
Figure 2.9. A schematic illustration of brain microdialysis.
2.5 METHODS FOR OVERCOMING THE POOR BRAIN UPTAKE
OF DRUGS
Larger  molecular  weight  and  hydrophilic  drugs  tend  to  fail  in
the drug discovery process because of their poor ability to cross
BBB. However, only a few brain diseases consistently respond to
small lipid-soluble molecules (Ajay et al., 1999). Therefore, the
development of new brain targeting strategies and their
seamless integration into the drug design process is necessary
(Pardridge, 2003). There are both chemistry-based and biology-
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based approaches for developing new brain targeting strategies
(Pardridge, 2001a). The chemistry-based strategies rely on
passive diffusion of drugs across the BBB, whereas the biology-
based strategies for brain drug delivery are based on the
principle that there are numerous endogenous transport
systems within the BBB, and these transporters are capable of
transporting drug molecules into the brain.
2.5.1 Improving the physicochemical properties of drugs
The paracellular route across the BBB is efficiently restricted by
tight junctions. Therefore, the physicochemical properties of
drug molecules have to be optimal for transcellular uptake in
order to enable the passive permeation across the BBB. These
properties are mentioned in Table 2.1. A very simple approach
to increase the CNS entry of polar molecules would be the
masking of polar functionalities. This is sometimes referred to as
the lipidization of molecules (Pardridge, 2007a). In practice,
lipidization through lipophilic drug analogues often results in
diminished therapeutic effect, due to decreased activity of the
analogues or increased toxicity (Rautio et al., 2008). Lipidization
through  prodrugs  offers  a  possibility  for  a  more  efficient  CNS
delivery of polar drugs without compromising their
pharmacological effect or safety. Prodrugs, being more
lipophilic than the parent drug, enter the CNS more readily, and
are then converted back to the parent drug within the CNS
(Anderson, 1996). However, lipophilic prodrugs share some
problems with lipophilic drug analogues which limit the
usefulness of the lipidization approach. Lipophilic modifications
can lead to an increase in molecular weight of the drug, and the
effect of molecular weight on molecule diffusion through
biological membranes has been well documented. Increased
lipid solubility not only increases permeation across the BBB,
but also permeation across all other biological membranes in the
body. Therefore, the increased BBB permeability is offset by
increased plasma clearance and reduced AUC and there may be
little increase in brain uptake of the drug, even though the BBB
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permeability has been greatly enhanced. Increased lipid
solubility  of  a  drug  may  enhance  drug  binding  to  plasma
proteins, which can lead to a low free plasma concentration of
the drug. Since it is the concentration gradient of the free
fraction of the drug that acts as the driving force across the BBB,
the enhanced membrane permeation caused by lipid solubility
can be offset by plasma protein binding. Probably the most
important factor that limits the usefulness of lipidization is high
non-specific brain tissue binding of lipophilic drugs. The
enhanced brain-to-plasma ratio and brain concentration of
lipophilic prodrugs or analogues is often due to non-specific
brain tissue binding (Summerfield et al., 2006; Friden et al., 2007;
Jeffrey and Summerfield, 2007). The optimization of drug brain
uptake by improving the brain-to-plasma ratio has been the
cornerstone of drug brain targeting in the past. However, as
recent studies show, the optimization of this parameter is often
futile, instead it is the free concentration in the brain that should
be optimized (Jeffrey and Summerfield, 2007; Hammarlund-
Udenaes et al., 2008; Liu et al., 2008). Despite several limitations,
many lipidization prodrug strategies have been proposed as
ways to achieve enhanced drug brain uptake (Oldendorf et al.,
1972; Anderson, 1996; Rautio et al., 2008).
2.5.2 Carrier-mediated uptake
Several specific carrier-mediated transporters have been
identified at the brain capillary endothelium that forms the BBB
e.g. LAT, MCT1 and GluT1 (Pardridge and Oldendorf, 1977). As
many drug molecules have similar structural properties to
endogenous substrates, it is clear that some membrane
transporters can also participate in drug transport (Tamai and
Tsuji, 2000). In many cases it is pure coincidence that the drugs
are able to utilize a transporter for BBB permeation. Moreover,
making chemical drug modifications in such a way that the
drug can be recognized by specific transporters, but still
maintaining its therapeutic efficacy, has proven to be very
challenging (Rautio et al., 2008). However, those drugs which
38
can utilize BBB transporters serve as good examples that the
transporters present at the BBB are able to carry molecules other
than their endogenous substrates.
One attractive approach to utilize BBB transporters is to
conjugate an endogenous transporter substrate to the active
drug molecule in a bioreversible manner; i.e., to utilize the
prodrug  approach.  The  prodrug  should  be  designed  in  such  a
way that it is recognized by the specific transporter mechanism
at the BBB, and transported across the BBB to brain tissues,
where the release of an active drug from the prodrug should
predominantly take place. However, the CNS drug delivery via
prodrugs can be compromised because of premature systemic
bioconversion of the prodrug, although the structural
requirements for transporter recognition are fulfilled. Moreover,
the prodrugs have to compete with endogenous substrates for
the transporters (del Amo et al., 2008). In addition, as the
transporters located in the BBB may also be present in other
tissues and there can be overlap of substrates with other
transporters, the prodrug may be channeled also into other
tissues. The plasma protein binding of highly bound drugs may
decrease significantly due to hydrophilic nutrient promoiety
(van de Waterbeemd et al., 2001). Therefore, the systemic
pharmacokinetics may change e.g. the higher free concentration
of drugs can increase the brain uptake due to increased
concentration gradient. The addition of a nutrient promoiety to
drug molecule often increases the hydrophilicity of the
molecule. Therefore, the passive brain uptake may be decreased
due to lower LogP (Fischer et al., 1998; Summerfield et al., 2007).
High hydrophilicity of prodrugs often leads to a decrease in the
non-specific brain tissue binding. Therefore, the free
concentration of the drug in brain parenchyma may not be
changed, even though the whole brain concentration is
decreased (Jeffrey and Summerfield, 2007; Summerfield et al.,
2007). The major advantage of nutrient mimicking prodrugs
over  lipophilic  prodrugs  or  drug  analogues  is  their  ability  to
maintain BBB permeability without increasing lipophilicity. In
addition, nutrient mimicking prodrugs may gain transporter
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mediated access into the intracellular compartments of the
brain. It has been postulated that the optimization of the CNS
uptake should be integrated early into the drug discovery
process. However, some brain targeting strategies, such as
prodrug design can be utilized later in the drug discovery
process, if the parent drug fails to cross the BBB sufficiently. The
carrier-mediated transporter utilizing prodrug strategy has been
studied most extensively for LAT1 and GluT1 systems (Walker,
1994; Halmos et al., 1996; Bonina et al., 1999; Bonina et al., 2003;
Fernandez et al., 2003).
The utilization of LAT1 in brain drug delivery
LAT1 has been suggested to contribute in the transport of
several clinically useful amino acid mimicking drugs, such as L-
dopa, melphalan, baclofen, 3-O-methyldopa, alpha-
methyltyrosine, gabapentin, alphamethyldopa, and thyroid
hormones, thus demonstrating the ability of this transporter to
be utilized in drug delivery (Cornford et al., 1992; Deguchi et al.,
1995; Gomes and Soares-da-Silva, 1999a; Gomes and Soares-da-
Silva, 1999b; Ritchie et al., 1999; Uchino et al., 2002). It should be
not surprising that all of these drugs bear a very close structural
resemblance to endogenous LAT1-substrates. The LAT1-
mediated brain uptake of these drugs seems to be a coincidence
and they were not designed to utilize LAT1. Although, there are
these examples of LAT1 utilizing drugs, the design of novel
drugs that are able to cross the BBB via LAT1 and still maintain
their therapeutic activity might be difficult. Therefore, a
different approach to utilize LAT1 has been suggested, such as
the  conjugation  of  drug  molecules  with  amino  acids  by  a
bioreversible bond i.e. by using a prodrug approach (Walker,
1994; Killian et al., 2007).
Drug molecules can be conjugated with amino acids that bear a
functional group suitable for prodrug bond in their side chain.
The conjugation from the side chain leaves the functional
groups necessary for the LAT1 affinity available. Once the
prodrug has crossed the BBB it needs to release the parent drug.
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Evidence acquired by determining the affinity of four melphalan
analogues suggests the binding affinity for LAT1 is dependent
not  only  upon  side  chain  hydrophobicity  but  upon  the  3D
structure of the side chain (Fig. 2.10) (Smith, 2005). It seems that
the meta-position of the side chain is the most favourable
position to attain high affinity for LAT1. Moreover, there is
some evidence that the maximal transport velocity decreases
with the substrate size. The effect of sterical hindrance on the
maximum uptake velocity was elegantly shown in the study of
(Takada et al., 1992). The affinity, transport velocity and PA
product of melphalan and melphalan analogoues were
determined with in situ rat brain perfusion technique. One
melphalan analogue, DL-NAM, showed higher affinity for LAT1
and maximum PA product compared to melphalan. In addition,
the Km of DL-NAM has significantly lower compared to Km of L-
phenylalanine and L-leucine. However, the maximum transport
velocity in situ was 20 times lower compared to melphalan and
150 times lower compared to L-phenylalanine in in situ
perfusion experiments. This indicates that though, DL-NAM
does  bind  to  LAT1  with  high  affinity,  the  presence  of  a  bulky
side chain leads to decreased transport velocity and the LAT1-
mediated uptake becomes saturated at low concentrations
(Takada et al., 1992). Despite the low uptake velocity, DL-NAM
is an excellent candidate for LAT1-mediated brain uptake and
serves as good example that LAT1 can be utilized for CNS drug
delivery. DL-NAM  has  higher  affinity  for  LAT1  than  the
endogenous substrates and therefore its plasma concentration
can remain low and still achieve LAT1-mediated brain uptake.
In addition, high affinity for LAT1 and high maximum PA
product indicates that DL-NAM is efficiently transported into
cells which express LAT1, such as brain cells and some cancer
cells (Takada et al., 1992).
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Figure 2.10. Structures  and Ki values  for  LAT1 binding  of  four
positional isomers of DL-NAM with the nitrogen mustard in
either the ortho (DL-2-NAM-8), meta (DL-2-NAM-5,-7) or para
(DL-2-NAM-6) positions (Smith, 2005).
LAT1 exhibits poor affinity for some amino acids is due to
hydrophilic functional group in the side chain. This functional
group can be used to link the parent drug with the amino acid
and as the hydrophilic functional group is masked from the side
chain,  the  resulting  prodrug  may  have  good  affinity  for  LAT1.
This  approach  enlarges  the  group  of  possible  amino  acids  that
can be utilized. In addition, it is possible to design and
synthesize new amino acid mimicking molecules,  which can be
used as promoieties. However, natural amino acids have some
advantages compared to their synthetic counterparts. Natural
amino acids are cheap and readily available. Furthermore, the
effects of natural amino acids on human body are known, and
when  using  natural  amino  acids,  the  risk  of  side  effects  in  the
brain caused by the released amino acids is lower compared to
synthetic promoieties.
There are certain limitations to the utilization of LAT1. LAT1
transporters in the BBB are normally saturated by the amino
acids present in plasma. The total concentration of relevant
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amino acids in plasma ranges from 0.4 mM to 2.3 mM, and their
average inhibition constant (Ki) to LAT1 is about 70–100 µM
(Huang et al., 1998). Therefore, in order to utilize the LAT1
system, the drugs and prodrugs have to compete with plasma
amino acids, and the affinity of the compounds for LAT1 has to
be high. In a recent review, it was reported that LAT1-mediated
brain uptake of L-dopa and melphalan is limited because LAT1
is saturated (del Amo et al., 2008). The LAT1-mediated L-dopa
and melphalan transport across the BBB is reduced by 98-99.6%
and 98.7-99.7% by 400-2300 µM concentration of amino acids,
respectively. However, as was shown with DL-NAM, molecules
with higher affinities than endogenous LAT1 substrates can be
designed. The drugs should also cross the abluminal membrane,
and  as  there  is  high  surplus  of  amino  acids  in  the  cytosol
compared  to  the  drug,  most  probably  only  a  minor  fraction  of
the efflux function of LAT1 is used by the drugs (del Amo et al.,
2008). Furthermore the putative Na+- dependent large neutral
amino acid transporter may pump drugs from the brain to the
blood circulation (Hawkins et al., 2005). LAT1 and other amino
acid transporters are also expressed in tissues other than the
BBB. This may lead to accumulation of the substrates into these
tissues. With systemic administration, the prodrug bonds
between the parent drug and amino acids are most likely
susceptible to degradation by enzymes which are present in
many tissues, not solely in the brain parenchyma. This can lead
to the premature release of the parent drug in peripherial
tissues. As the brain uptake of drugs is efficiently limited by the
BBB, even small improvement of brain uptake may be adequate.
Although L-dopa has been in clinical use for more than 40 years,
there are not many drugs in clinical use or published prodrugs
that utilize LAT1 for brain uptake (Pardridge, 2003). This may
be due to poor understanding of the limitations and possibilities
of LAT1 utilization. It seems that LAT1 utilization could be most
useful for small molecular weight drugs, which are not able to
cross the BBB because of their hydrophilicity. In addition, drugs
with high plasma protein binding may benefit from this
prodrug strategy. With an amino acid promoiety, it may be
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possible to enhance the brain uptake of hydrophilic drugs
without increasing the lipophilicity. Therefore, the non-specific
binding to brain tissue and the increased distribution into other
tissues than brain should be avoided. In addition, the presence
of amino acid transporters at the brain parenchyma may
increase the cellular uptake of amino acid prodrugs, which
would be useful, if the target protein of the parent drug is
located inside the cell (Thurlow et al., 1996; Simpson et al., 2007).
Gapapentin has been shown to have higher brain distribution
volume than its lipophilicity would indicate, and it has been
concluded that the cellular uptake of gabapentin is carrier-
mediated (Friden et al., 2007). In fact it has been proposed that
the gabapentin uptake into astrocytes and synaptosomes is
rapid, and the uptake is mediated by the same transporter as the
uptake of L-leucine (Su et al., 1995; Wang and Welty, 1996).
LAT1 is a good option for a carrier-mediated transporter
targeting strategy, because there are several examples that
compounds other than LAT1 endogenous substrates are able to
utilize this transporter to cross the BBB. In addition, the rational
design of LAT1 substrates is possible, because there is
understanding of what the structural properties make molecules
LAT1 substrates. Furthermore, amino acids have suitable
functional groups which can be utilized for the formation of
prodrug bond between the amino acid and drug molecule.
Examples of prodrugs that have been designed to utilize LAT1 for
brain uptake
The studies published so far involving LAT1-mediated brain
uptake of prodrugs are LAT1 substrate uptake inhibition
studies. These studies are a simple and quick way to determine
the ability of the prodrug to inhibit the uptake of endogenous
substrate, and therefore, demonstrate its ability to bind to LAT1.
However, these studies do not provide any insight into whether
the prodrugs were able to cross the BBB. For example, L-cysteine
was conjugated with the anticancer agent 6-mercaptopurine
(Fig. 2.11) and a model compound 2-methyl-1-propanethiol
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(Killian  et  al.,  2007).  The  prodrugs  were  able  to  inhibit  LAT1-
mediated brain uptake of [14C]L-leucine using an in situ rat brain
perfusion technique, which indicated that the prodrugs are able
to bind to LAT1. It has been reported that an antiviral agent
phosphonoformate L-tyrosine conjugate could inhibit the
transport of [3H]L-tyrosine in porcine brain microvessel
endothelial cells (Fig 2.11) (Walker, 1994). In another study, p-
nitro and p-chlorobenzyl ether conjugates of L-tyrosine inhibited
the transport of [3H]L-tyrosine in rabbit corneal cell line (Fig.
2.11) (Balakrishnan et al., 2002). These results indicate that L-
tyrosine and L-cysteine conjugates are able to bind to the LAT1-
transporter. However, the ability of these conjugates to cross the
cell membranes has not been evaluated. Moreover, the in vivo
brain uptake of these conjugates cannot be estimated from the in
situ brain  perfusion  and in vitro results. However, there is an
example of in vivo study  on  amino  acid  prodrugs.  The
anticonvulsant activity of nipecotic acid L-tyrosine ester was
studied in an in vivo epilepsy rat model (Fig. 2.11) (Bonina et al.,
1999). The prodrug was able to reach therapeutically active
concentrations in the CNS. However, the mechanism of brain
uptake remains unclear as the prodrug is very lipophilic and no
further BBB transport studies were conducted for this prodrug.
In addition to BBB permeation, the conjugates should release the
parent drug in the brain parenchyma and be stable in the
systemic circulation. Some estimation of the prodrug stability
can be made with in vitro tissue homogenate studies. However,
in vivo studies need to be conducted before any conclusions of
the stability can be made.
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Figure 2.11. Structures of amino acid conjugates tested in vivo, in
vitro or in situ (Walker, 1994; Bonina et al., 1999; Balakrishnan et
al., 2002; Killian et al., 2007).
The utilization of GluT1 in brain drug delivery
GluT1 is present both on the luminal and the abluminal
membranes of the endothelial cells making up the BBB (Farrell
and Pardridge, 1991). GluT1 transports glucose and other
hexoses, and has the highest transport capacity of all the carrier-
mediated transporters present at the BBB, being therefore an
attractive transporter for prodrug delivery (Anderson, 1996).
The utilization of GluT1 for carrier-mediated brain uptake has
been studied with several techniques (Battaglia et al., 2000;
Fernandez et al., 2003; Garcia-Alvarez et al., 2007). However, the
results from these studies are somewhat inconsistent. In vitro
studies have revealed that glycosyl conjugates bind to GluT1
and inhibit the uptake of substrates like glucose. Moreover,
some structure activity relationship data are available, which are
partially consistent with a model for the exofacial configuration
and the substrate binding site of GluT1 (Fernandez et al., 2003;
Mueckler and Makepeace, 2008). There are also data that show
that some of the conjugates that bind to GluT1 are not able to
cross the cell membrane via GluT1 and they act merely as
glucose uptake inhibitors (Halmos et al., 1996; Garcia-Alvarez et
al., 2007). Results from in vivo experiments demonstrated that
glucose conjugates were able to cross the BBB in vivo and release
the parent drug in pharmacologically active amounts in the CNS
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(Fig. 2.13) (Bonina et al., 1999; Battaglia et al., 2000; Bonina et al.,
2003). However, the mechanism of the brain uptake remains
unclear. In addition, the bioreversible bond between the parent
drug and glucose is often labile, which limits the use of these
prodrugs. Moreover, there is a risk involved when GluT1 is
utilized for brain uptake. The efficient brain uptake of glucose is
essential to maintain normal cerebral function and thus the
supply of glucose uptake could be disrupted, if GluT1 is utilized
via prodrugs. However, GluT1 utilization is still a potential
strategy for enhanced brain uptake of prodrugs. In particular,
the brain uptake of small hydrophilic drug molecules could be
enhanced by inclusion of a glucose promoiety. The vast
transport capacity and the poor affinity of the endogenous
substrate glucose can be possibly utilized with good prodrug
design.  If  the  affinity  of  the  prodrug  for  GluT1  is  much higher
than the affinity of glucose, advantage could be made of the vast
capacity of GluT1 to handle low plasma drug concentrations. In
addition, the sufficient stability of the glucose prodrugs needs to
be addressed, if new prodrugs are designed for per oral drug
administration.
Examples of prodrugs that have been designed to utilize GluT1 for
brain uptake
The glycosylation strategy has been utilized in an attempt to
increase the brain uptake of several CNS active drugs, such as
dopamine, chlorambucil, 7-chlorokynurenic acid and GW196771
(Fig. 2.12 and 2.13) (Halmos et al., 1996; Battaglia et al., 2000;
Fernandez et al., 2000; Bonina et al., 2003; Angusti et al., 2005).
The studies considering the uptake mechanism of glucose
prodrugs have been performed in vitro by determining the
ability of the glycosyl conjugates to inhibit the uptake of
radiolabeled substrate. In addition, some in vitro studies also
include the determination of the cellular uptake of the prodrugs.
A glucose–chlorambucil derivative was able to inhibit the
uptake of [14C]D-glucose into human erythrocytes (Halmos et al.,
1996). However, in these in vitro uptake studies, the prodrug
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was found to be an inhibitor rather than a substrate of GluT1.
Several glycosyl derivatives of dopamine were synthesized and
tested for the affinity of the prodrugs for GluT1 in human
erythrocytes (Fernandez et al., 2003). Dopamine was linked to
glucose with different linkers at the C-1, C-3 and C-6 positions
of glucose (Fig. 2.12). The results of glucose uptake inhibition
revealed that the glucose derivatives that were conjugated at
position C-6 had the best affinity for GluT1. There was also a
difference in the affinity when carbamate or succinamate was
used as linkers between dopamine and the promoiety, with the
carbamate prodrug having better affinity for the carrier. In
addition, human retinal pigment epithelium cells were used to
determine the cellular uptake mechanism of the dopamine-
glucose conjucate (Dalpiaz et al., 2007). The prodrug was
obtained by coupling dopamine to D-glucose via a succinic
spacer from the C-3 position. The result suggested that the
dopamine  prodrug  was  able  to  inhibit  the  uptake  of  [3H]3-O-
methylglucose in a concentration-dependent manner. In
addition, it was observed that the dopamine prodrug was able
to permeate into the cells, and the uptake of the prodrug was
significantly inhibited in the presence of 10 mM D-glucose. The
cellular uptake of several glucose conjugates of dopamine
derivatives into erythrocytes was determined in the presence
and absence of GluT1 inhibitors (Garcia-Alvarez et al., 2007).
The dopamine derivatives were conjugated with glucose at the
C-6 position based on the earlier studies of the research group,
indicating that conjugation at C-6 position resulted in the best
affinity for GluT1. There was a difference in the uptake rate of
the glucose-dopamine derivative conjugates into erythrocytes.
These results indicated that hydrophilic derivatives displayed
the poorest uptake into the cells. In addition, two GluT1
inhibitors, maltosyl isothiocyanate and cytochalasin B, were not
able to inhibit the uptake, indicating that the cellular uptake of
the conjugates was not GluT1-mediated.
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Figure 2.12. Examples of dopamine-glucose prodrugs
(Fernandez et al., 2003; Dalpiaz et al., 2007).
Some studies with glucose conjugates have been performed in
mice and rats in vivo. Glycosyl derivatives of dopamine that
were conjugated with a succinyl linker did not exhibit any
ability to induce recovery of the motor activity of mice
pretreated with reserpine (Fernandez et al., 2000). This was
attributed to slow the bioconversion rate of the prodrugs into
dopamine. In another study L-dopa and dopamine glycoside
prodrugs were synthesized by conjugating the parent drugs
with glucose at the C-3 position and galactose at the C-6
position by a succinyl linker with the aim of overcoming the
problem of the low BBB permeability of dopamine (Bonina et al.,
2003). The prodrugs were tested with classic dopaminergic
models, morphine induced locomotion in mice and reserpine-
induced hypolocomotion in rats. Both of the dopamine
glycosidic prodrugs were more active in reversing the reserpine-
induced hypolocomotion in rats than L-dopa or the L-dopa
prodrugs. For example, in reducing morphine-induced
locomotion in mice, the galactose-dopamine conjugate was the
most effective and glucose-dopamine had the lowest efficacy of
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all the tested prodrugs. However, the glucose-L-dopa prodrug
was more effective than the galactose-L-dopa prodrug. Thus, it
seems that by conjugating dopamine with glycosides, the
pharmacological efficacy had been increased but the mechanism
of brain uptake remained unclear. In other words, the increased
pharmacological activity of galactose-dopamine conjugate might
not be due to GluT1-mediated increased brain permeability. The
concentration of 7-chlorokynurenic acid and kynurenic acid in
the rat brain was determined with microdialysis after systemic
injection of 7-chlorokynurenic acid with two glucose conjugates
of 7-chlorokynurenic acid (Fig. 2.13) (Battaglia et al., 2000). The
glycosylation increased the brain uptake of the parent drug, but
the mechanism responsible for the increased uptake was
unfortunately not conclusively demonstrated in that study.
Figure 2.13. The structures of D-glucose prodrugs tested in vivo
(Halmos et al., 1996; Bonina et al., 1999; Battaglia et al., 2000;
Angusti et al., 2005).
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3 Aims of the study
The main objective of this doctoral thesis was to develop
prodrugs that are able to cross the blood-brain barrier via LAT1
or Glut1 transporters. This included the design of the prodrugs,
evaluation of the physicochemical properties and evaluation of
their brain uptake mechanism and the extent of the brain uptake
with in vitro, in situ and in vivo methods. The more specific aims
were:
1. To modify and combine in vitro, in situ and in vivo
methods, in order to evaluate the mechanism of brain
uptake, and the distribution in the brain parenchyma of
developed amino acid and glucose prodrugs.
2. To design amino acid prodrugs of ketoprofen, which are
able to bind to LAT1 and cross the blood-brain barrier.
3. To determine whether amino acids other than LAT1
substrates be used to form prodrugs that are LAT1
substrates. This would enable the use of different
prodrug bonds between the parent drug and the amino
acid. L-Lysine  was  chosen  as  a  promoiety,  because  it  is
not  a  LAT1  substrate  and  it  can  be  conjugated  with
ketoprofen via the amide bond on its side chain.
4. To determine the ability of the amino acid prodrugs to
deliver ketoprofen into the brain parenchyma in vivo.
5. To design D-glucose prodrugs of ketoprofen and
indomethacin which are able to bind to GluT1 and cross
the blood-brain barrier.
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4 Experimental
4.1. ANALYTICAL METHODS
4.1.1 HPLC assay
The prodrug and parent drug concentrations were analyzed by
Agilent 1100 HPLC system (Agilent Technologies Inc.,
Waldbronn, Karlsruhe, Germany) that consisted of a binary
pump G1312A, a vacuum degasser G1379A, an automated
injector system autosampler Hewlett Packard 1050, an UV-
detector Hewlett Packard 1050 variable wavelength detector and
an analyst software Agilent ChemStation for LC Systems Rev.
A.10.02. The detector wavelength was set at 256 nm when
ketoprofen or ketoprofen prodrug were analyzed and at 222 nm
when indomethacin prodrugs were analyzed. A mixture of
acetonitrile and a 0.02 M phosphate buffer solution at a flow rate
of 1 mL/min was used as a mobile phase. Reversed-phase HPLC
was conducted with a Zorbax RP-18 column (150 mm × 4.6 mm,
5 µm, Agilent Technologies, Little Falls, Wilmington, DE).
4.1.2 Liquid chromatography-electrospray tandem mass
spectrometry (LC-MS)
The quantitative determination of ketoprofen-lysine amide and
ketoprofen in plasma and brain samples was performed using
liquid chromatography-electrospray tandem mass spectrometry
(LC-MS) (Agilent 1200 Series Rapid Resolution LC System,
Agilent Technologies, Waldbronn, Germany) coupled with an
electrospray ionization (ESI) triple quadrupole mass
spectrometer (Agilent 6410 Triple Quadrupole LC/MS, Agilent
Technologies, Palo Alto, CA). The chromatographic separation
was performed on a reversed phase column by gradient method
with acetonitrile and water, both containing 1% formic acid at a
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flow-rate of 0.3 mL/min. Positive electrospray ionization and
selected reaction monitoring were used for the detection of
ketoprofen-lysine amide (m/z 383→ 84) and ketoprofen (m/z 255
→ 209).
4.1.3 Brain and plasma sample preparation
L-Tyrosine-ketoprofen, L-lysine-ketoprofen, D-glucose-
ketoprofen and D-glucose-indomethacin prodrugs and
ketoprofen were isolated from the rat brain homogenate
samples by liquid-liquid extraction. A complete brain
hemisphere was homogenated with 2.5 mL of water to produce
3.0 mL of homogenate. The samples were acidified with 300 µl
of  2  M  hydrochloric  acid  and  vortexed  for  5  min.  Solvent  was
added and aliquots were vortexed for 2 min, and centrifuged for
10 min (7500 × g) after which the supernatants were collected.
The supernatants were applied to the preconditioned and
equilibrated C18 solid phase extraction cartridges. The extracted
supernatants were evaporated to dryness under a nitrogen
stream  at  40  °C.  Prior  to  LC-MS  or  HPLC-UV  analysis,  the
samples were reconstituted in 400 µL acetonitrile-water
solution, and filtered.
L-Lysine-ketoprofen prodrug and ketoprofen and were isolated
from the plasma samples by protein precipitation. Plasma (100
µL)  was  acidified  with  50  µL  of  1  M  hydrochloric  acid  and
vortexed  for  5  min.  Acetonitrile  (1.0  mL)  was  added  and  the
samples were vortexed for 2 min, after which time the samples
were centrifuged for 5 min (5500 × g). The supernatants were
collected, and the samples were evaporated to dryness under a
nitrogen stream at 40 °C. Prior to LC-MS or HPLC-UV analysis,
samples were reconstituted in 400 µL acetonitrile-water
solution, and filtered.
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4.2 PHYSICOCHEMICAL PROPERTIES OF THE PRODRUGS
4.2.1 Apparent partition coefficients
The apparent partition coefficients (LogD) were determined at
room temperature by a 1-octanol-phosphate buffer system at pH
7.4. Before use, the 1-octanol was saturated with phosphate
buffer for 24 h by stirring vigorously. A known concentration of
compound in phosphate buffer was shaken 30 min (pH 7.4),
with a suitable volume of 1-octanol. After shaking, the phases
were separated by centrifugation at 14000 rpm for 4 min. The
concentrations of the compounds in the buffer phase before and
after partitioning were determined by HPLC.
4.2.2 Polar surface area
Polar surface areas of prodrugs were calculated using the
method by Ertl et al. (Ertl et al., 2000) implemented in Molecular
Operating Environment.
4.2.3 In vitro brain tissue and plasma protein binding
Drug-naive animals were sacrificed, the brain was removed, and
3 volumes of a phosphate buffered saline (pH 7.4) was added.
The brains were homogenized on ice with an ultrasonic probe
after which the drug was added. Blood was recovered from
anesthetized animal with heart puncture and plasma was
separated by centrifugation. Equilibrium dialysis of 400 µL of
homogenate or plasma and 600 µL of buffer was performed in
triplicate for 4 h at 37 °C in Single-Use RED Plate with an 8-kDa
cutoff dialysis membrane (Thermo Scientific, Rockford, IL). The
buffer to homogenate or plasma concentration ratio was
calculated, which was used to calculate the in vitro brain tissue
and plasma protein binding (Kalvass and Maurer, 2002; Friden
et al., 2007).
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4.2.4 CHEMICAL AND ENZYMATIC STABILITY OF THE
PRODRUGS IN VITRO
The rate of chemical hydrolysis of the prodrugs was studied in
aqueous phosphate buffer solution of pH 7.4 (0.16 M, ionic
strength 0.5) at 37 °C. An appropriate amount of the prodrugs
was dissolved in 10 mL of preheated buffer and the solutions
were placed in a thermostatically controlled water bath at 37 °C.
At appropriate intervals, samples were taken and analyzed for
remaining prodrug by the HPLC. Pseudo-first-order half-time
(t1/2) for the hydrolysis of the prodrugs was calculated from the
slope of the linear portion of the plotted logarithm of remaining
prodrug versus time.
The rate of enzymatic hydrolysis of the prodrugs was studied at
37 °C in 80% (v/v) rat serum, in 20% rat brain homogenate and
in 50% rat liver homogenate. The concentration of esterase
enzymes in the homogenates was not determined. The mixtures
were kept in a water bath at 37 °C, and 0.2 mL of serum/buffer
or homogenate/buffer mixture was withdrawn and added to 0.2
mL of acetonitrile to precipitate protein from the sample. After
immediate mixing and centrifugation, the supernatant was
analyzed for the remaining prodrug and released the parent
drug by the HPLC. Pseudo-first-order half-time (t1/2) for the
hydrolysis of the prodrugs was calculated from the slope of the
linear portion of the plotted logarithm of remaining prodrug
against time.
4.3 ANIMALS
Adult male Wistar rats (250 g) were supplied by the National
Laboratory Animal Centre (Kuopio, Finland) for the in vivo
studies. Rats were anesthetized with ketamine (90 mg/kg, i.p.)
and xylazine (8 mg/mL, i.p.).
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4.4 IN SITU RAT BRAIN PERFUSION TECHNIQUE
In the present study, the in situ rat brain perfusion technique
was used for the determination of the brain uptake mechanism
of the prodrugs, since it has advantages over both in vivo and in
vitro techniques. The experimental conditions can be easily
manipulated to study saturable processes such as carrier-
mediated uptake, and moreover, experimental conditions can be
used  that  would  be  toxic  in  the in vivo situation. The most
important advantage over in vivo experiments is the simplicity
of the pharmacokinetics that makes the accurate determination
of the uptake mechanism of the prodrug possible (Foster and
Roberts, 2000; Summerfield et al., 2007). In vivo techniques take
into  account  not  only  BBB  penetration  but  also  binding  to
plasma proteins, metabolism, and clearance and there is
significant value in removing some of this complexity and
assessing brain penetration at the level of the BBB in situ.
Furthermore, the in situ technique provides deeper insight into
the molecular descriptors that are crucial for BBB penetration
(Summerfield et al., 2007). The most important advantage over
in vitro techniques is that the BBB is in its normal physiological
state when in situ technique is used.
Modified in situ rat brain perfusion technique (Smith and Allen,
2003; Killian et al., 2007) was used to quantify the brain uptake
and the transport mechanism of the prodrugs at the BBB. The
right carotid artery of the rats was exposed. The right external
carotid artery was ligated, and the right common carotid artery
was cannulated with PE-50 catheters filled with 100 IE/mL
heparin. The right occipital and the right pterygopalatine
arteries were left open. The blood flow of the rats was
interrupted by severing the cardiac ventricles. The perfusion
fluid was infused through the common carotid artery at the rate
of 10 mL/min for 30‒60 seconds using Harvard PHD 22/2000
syringe pump (Harvard apparatus Inc., Holliston, MA). After
decapitation, the skull was opened and brain sections (10‒30
mg)  were  excised  from  six  different  regions  of  the  right  brain
hemisphere (frontal cortex, parietal cortex, occipital cortex,
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hippocampus, caudate nucleus and thalamus). Left parietal
cortex was used as the control. All samples were analyzed for
radioactivity by liquid scintillation counting (Wallac 1450
MicroBeta; Wallac Oy, Finland). Brain samples were dissolved
in 0.5 mL of Solvable™ (PerkinElmer, Boston, MA) overnight at
50 °C and liquid scintillation cocktail (Ultima Gold,
PerkinElmer, Boston, MA) was added before analyzing the
samples. The perfusion medium consisted of a pH 7.4
bicarbonate-buffered physiological saline (128 mM NaCl, 24 mM
NaHCO3, 4.2 mM KCl, 2.4 mM NaH2PO4, 1.5 mM CaCl2, 0.9 mM
MgCl2 and 9 mM D-glucose). The solution was filtered, heated to
37 °C and bubbled with 95% O2 /  5% CO2 to attain steady state
gas levels within the solution. The in situ rat brain technique
was validated by measuring the intravascular volume (Vv) as
estimated by [14C]sucrose and by quantifying the brain uptake of
[3H]diazepam, [14C]urea  and  [14C]L-leucine. All radiolabeled
compounds used in the in situ rat brain perfusion technique
were purchased from PerkinElmer (Boston, MA) and were
uniformly labeled.
4.5 DETERMINATION OF THE BRAIN UPTAKE MECHANISM
FOR PRODRUGS
The ability of prodrugs to bind to LAT1 or GluT1 was studied
with the in situ rat brain perfusion technique. The 100% PA
products of [14C]L-leucine  and  [14C]D-glucose were determined
after 30 s perfusion of 0.2 µCi/mL [14C]L-leucine or [14C]D-
glucose solution. In the competition studies, the radiolabeled
substrates were co-perfused with prodrugs for 30 s. In order to
study whether the binding of the prodrugs to the transporter
was reversible, the PA product of radiolabeled substrate was
determined after perfusing rat brain first with the prodrug for
30 s, followed by washing the prodrug from the brain capillaries
with prodrug-free perfusion medium for 30 s and finally
perfusing the brain with radiolabeled substrate for 30 s.
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4.6 BRAIN UPTAKE STUDIES OF THE PRODRUGS
The brain uptake studies of the L-tyrosine-ketoprofen, L-lysine-
ketoprofen, D-glucose-ketoprofen and D-glucose-indomethacin
prodrugs  were  performed  with  the in situ rat brain perfusion
technique. The prodrugs were dissolved in dimethyl sulfoxide
(DMSO)  and  then  added  to  the  perfusion  medium  resulting  in
1% (v/v) DMSO solution. After adjusting the pH to 7.4, the
solution was filtered with 0.45 µm Millex-HV filters. The rat
brains were perfused 60 s with 37 °C perfusion medium
containing the prodrug. After perfusion, the remaining prodrug
was washed from the brain vasculature with cold prodrug-free
perfusion medium (5 °C) for 30 s. The prodrug concentration of
the perfusion medium was analyzed by the HPLC after each
perfusion to confirm that the prodrug had stayed intact. The
brain uptake was also determined by inhibiting carrier-
mediated uptake non-specifically at a low temperature. The
brain capillaries were first washed for 30 s with cold prodrug-
free perfusion medium (5 °C), followed by perfusion for 60 s
with cold prodrug solution (5 °C),  and washed again with cold
prodrug-free perfusion medium (5 °C).
4.7 CAPILLARY DEPLETION ANALYSIS
Capillary depletion analysis was carried out as previously
described by (Triguero et al., 1990). Brain samples (right brain
hemisphere) were weighed and homogenized in glass
homogenizer with 1.5 mL of physiological buffer. After
homogenization, 2 mL of 26% dextran solution was added and
the mixture was further homogenized. The homogenate was
separated into two microcentrifuge tubes and centrifuged 15
minutes (5400 × g, 4 °C). The resulting supernatant consisting of
the brain parenchyma and the pellet rich in cerebral capillaries
were separated and prepared for analysis with the HPLC.
Values of the volume of distribution (Vd) for the homogenate,
supernatant fraction and the capillary pellet were calculated.
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4.8 IN VIVO INTRAVENOUS BOLUS INJECTION METHOD
L-Lysine-ketoprofen prodrug and ketoprofen were dissolved in
0.9% NaCl solution of pH 7.4 resulting in 30 mM concentration.
Then, a 0.2 mL bolus injection of either drug was administered
into the cannulated jugular vein of the rats, and plasma and
brain concentrations were determined at the following time
points: 10, 30, 60, 120 and 300 min. For Vd and  clearance  (CL)
determinations the plasma samples were taken in following
time points: 2, 5, 10, 15, 30, 45, 60, 90 and 120 min. The plasma
samples were drawn from the cannulated jugular vein at
different time points and the brain were removed after the rats
were sacrificed. Ketoprofen and prodrug levels in brain
parenchyma were calculated by correcting the measured brain
sample concentration for the cerebral vascular space component,
which was determined to be 0.0116 mL/g.
4.9 IN VIVO MICRODIALYSIS
A microdialysis guide cannula (MAB 6.10.IC, AgnTho’s AB,
Lidingö, Sweden) was implanted into the striatum (coordinates
from  bregma:  AP  +0.5  mm;  L  -3.0  mm;  DV  -3.8  mm)  under
chloral hydrate anesthesia (350 mg/kg i.p.). After a one week
recovery period, the rats were again anesthetized and a
concentric microdialysis probe (MAB 9.10.4; 4 mm exposed
membrane, 6 kDa cut-off, AgnTho’s AB) was inserted into the
striatum through the guide cannula. An intravenous
microdialysis probe (MAB 11.20.10; 10 mm exposed membrane,
6 kDa cut-off, AgnTho’s AB) was inserted into the left femoral
vein, and both probes were perfused with Krebs Ringer solution
(consisting  of  138  mM  NaCl,  1  mM  CaCl2,  5  mM  KCl,  1  mM
MgCl2 • 6H2O, 11 mM NaHCO3, 1 mM NaH2PO4 • H2O, and 11
mM D-glucose, pH 7.4) at a flow rate of 2 µl/min. For drug
administration, the right femoral vein was cannulated with
polyethylene tubing filled with saline and 20 IU/ml dalteparin.
The microdialysis probes were perfused for 80 min before
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intravenous drug administration, and the dialysate was
collected  as  ten  or  twenty-minute  fractions  for  5  hours  into
polypropylene vials (AgnTho’s AB). All dialysate drug
concentrations were corrected with recovery values. The
samples were frozen at -20 °C and stored at -80 °C until
analyzed.
4.10 IN VITRO RECOVERY OF MICRODIALYSIS PROBES
To estimate the true free drug concentration in brain ECF and
the blood probe calibration was performed in vitro for  both
probe types. The recovery was determined as the ratio of a drug
in the dialysate to the drug concentration (1 µM) in a non-stirred
bulk  Krebs  Ringer  solution  at  37  °C  (Cdial/Cbulk;  n=3  probes  for
each drug, 3 determinations per probe; flow rate 2 µl/min,
collection time 20 min).
4.11 EQUATIONS
All used equations are presented in chapter 2.4.1.
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5 LAT1 - Mediated brain
uptake of amino acid
prodrugs of ketoprofen
Abstract. LAT1 is expressed on the luminal and abluminal
membrane of the BBB capillary endothelial cells and it efficiently
transports large neutral L-amino  acids  into  the  brain.  The
efficient brain uptake of amino acids as well as some CNS drugs
via LAT1 suggests that the transporter could also be used to
target prodrugs into the brain. We describe a feasible means to
achieve carrier-mediated drug transport into the rat brain via
LAT1  by  conjugating  a  model  compound  to  amino  acids.  A
hydrophilic drug, ketoprofen, that is not a substrate for LAT1
was  chosen  as  a  model  compound.  Out  of  five  amino  acid
prodrugs of ketoprofen that were designed, synthesized and
evaluated, one prodrug L-tyrosine-ketoprofen ester showed
affinity  for  LAT1.  The  mechanism and the  kinetics  of  the  brain
uptake of the prodrug were determined with in situ rat brain
perfusion technique. The brain uptake of the prodrug was found
to be concentration dependent. In addition, LAT1 inhibitor
significantly decreased the brain uptake of the prodrug.
Therefore, our results show that the amino acid prodrug
approach can achieve brain uptake of small molecular weight
drugs in situ via LAT1.
Adapted with permission of the American Chemical Society from: Gynther
M., Laine K., Ropponen J., Leppänen J., Mannila A., Nevalainen T., Savolainen
J., Järvinen T., RautioJ.: Large neutral amino acid transporter enables brain
drug delivery via prodrugs. Journal of Medicinal Chemistry 51: 932-936, 2008.
© 2008 the American Chemical Society. All rights reserved.
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5.1 INTRODUCTION
Brain penetration is essential for drugs intended to act within
the CNS. The entry of drug molecules into the CNS is efficiently
governed by the BBB (Pardridge, 2003; Begley, 2004). Many
pharmacologically active drugs intended for CNS disorders fail
early in their development phase because they lack the
structural features essential for crossing the BBB and
distributing into the brain parenchyma. Therefore, CNS drugs
should be designed with appropriate brain penetration
properties (Liu et al., 2008). Good BBB penetration can be
achieved by designing highly permeable compounds and by
screening out efflux transporter substrates (Liu et al., 2008). One
attractive approach to achieve good BBB penetration and low
brain non-specific tissue binding, without losing the
pharmacological  activity,  is  to  utilize  the  prodrug  approach
(Rautio et al., 2008). The properties of a drug molecule can be
altered in a bio-reversible manner by conjugating the drug with
a suitable promoiety.
Several specific endogenous influx transporters e.g. LAT1 have
been identified on the brain capillary endothelial cells which
form the BBB. LAT1 is expressed on the luminal and abluminal
membranes of the capillary endothelial cells and it efficiently
transports neutral L-amino  acids  (e.g., phenylalanine and
leucine) into the brain. If one could achieve selective release of
the active drug in the target tissue, this would result in a
reduced plasma concentration of the drug and fewer peripheral
effects.
The  aim of  the  study was  to  design  and synthesize  amino  acid
prodrugs of ketoprofen and to evaluate their ability to cross the
BBB via LAT1. The mechanism of brain uptake of the prodrugs
was determined with in situ rat brain perfusion technique.
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5.2 RESULTS AND DISCUSSION
5.2.1 Design of the prodrugs
Ketoprofen was chosen as a model compound because it is a
fairly stable molecule in various mediums, it is easy to detect
with UV-detector or mass spectrometry and it has a carboxyl
group, which makes it easy to conjugate with various
promoieties. In addition, it has been proposed that non-steroidal
anti-inflammatory drugs may have some therapeutic effects in
CNS disorders, such as Alzheimer`s disease.
The prodrugs were designed to meet the requirements for LAT1
substrates based on the proposed LAT1 binding site model
(Uchino et al., 2002; Smith, 2005). That model states that a
potential LAT1 substrate should have a positively charged
amino group, a negatively charged carboxyl group and a
hydrophobic side chain. L-Tyrosine was selected because the
phenolic hydroxyl group enables the formation of ester bond
between ketoprofen and the amino acid (Fig. 5.1) L-
Phenylalanine and L-leucine prodrugs were synthesized in
order to confirm that free carboxylic and amino groups are
indeed required for LAT1 recognition. L-Phenylalanine and L-
leucine do not have suitable functional groups in their side
chains  for  prodrug  bond.  Therefore,  ketoprofen  has  to  be
conjugated with the amino acids either from the carboxylic or
the amino groups.
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Figure 5.1. Chemical structures of ketoprofen and the amino
acid prodrugs 1-5.
5.2.2 Chemical and enzymatic stability of the prodrugs
The degradation of the prodrugs was studied in aqueous buffer
solution of pH 7.4 at 37 °C. The degradation of L-tyrosine-
ketoprofen prodrug (1) followed pseudo-first-order kinetics
with a half-life  of  22.5 ± 1.4 hours (mean ± s.d.,  n=2).  Therefore,
the prodrug demonstrated sufficient chemical stability in
aqueous solutions for further evaluation.
If the target for a prodrug design is the site-selective drug
delivery to the CNS, the prodrug must not only be delivered to
its intended site of action, but its bioconversion should also be
selective (Anderson, 1996). 1 was  highly  susceptible  to
enzymatic hydrolysis as it was quantitatively cleaved to
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ketoprofen and L-tyrosine in 80% rat serum, in 20% rat brain
homogenate and in 50% rat liver homogenate. The enzymatic
hydrolysis followed pseudo-first-order kinetics, the half-lives
being 10.2 ± 0.4, 4.4 ± 1.8 and 2.8 ± 0.6 minutes (mean ± s.d., n=3)
in serum, brain homogenate and liver homogenate, respectively.
Therefore, 1 undergoes rapid bioconversion to ketoprofen and
L-tyrosine in the brain tissue. However, 1 is  also  highly
susceptible to enzymatic hydrolysis in both rat serum and liver
which may compromise its effective brain drug delivery.
5.2.3 In situ rat brain perfusion technique
In situ rat brain perfusion technique was used to evaluate
intravascular volume (Vv) of the rat brain, the cerebral perfusion
flow rate (F) and the brain capillary permeability-surface area
(PA) product of [14C]L-leucine and [14C]urea. The presence of
functional LAT1-transporters was evaluated based on recent
publications (Rousselle et al., 1998; Killian and Chikhale, 2001;
Smith and Allen, 2003; Killian et al., 2007). 0.2 µCi/mL
[14C]sucrose was used as a vascular marker to determine Vv and
to demonstrate the integrity of the BBB during brain perfusion
(Killian et al., 2007). The value of Vv was determined to be 0.0116
± 0.0013 mL/g (mean ± s.d., n=3). The integrity of the brain
capillaries was tested with 0.2 µCi/mL [14C]sucrose after
addition of 1% (v/v) of dimethyl sulfoxide (DMSO). The value of
Vv was 0.01032 ± 0.00098 mL/g (mean ± s.d., n=3) indicating that
the addition of 1% (v/v) of DMSO does not compromise the
integrity of the tight junctions between the endothelial cells.
A highly diffusible and lipophilic solute, [3H]diazepam, was
used to determine F under the test conditions (Rousselle et al.,
1998). The value of F for 0.2 µCi/mL [3H]diazepam was
determined to be 0.02846 ± 0.00395 mL/s/g (mean ± s.d., n=4).
The value of F for [3H]diazepam was also determined using 5 °C
perfusion medium and it was 0.02561 ± 0.0045 mL/s/g (mean ±
s.d., n=2). Similar F values indicate that the low temperature of
the perfusion medium did not have any effect on the passive
diffusion of [3H]diazepam across the BBB.
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The permeability of rat BBB in the test system was studied with
[14C]urea, a polar molecule with low BBB permeability
(Rousselle et al., 1998; Killian and Chikhale, 2001). PA product
of 0.2 µCi/mL [14C]urea was determined to be 0.00018 ± 0.000056
mL/s/g (mean ± s.d., n=3).  The low permeability of urea was in
agreement with previous studies (Rousselle et al., 1998; Killian
and Chikhale, 2001).
The presence of functional LAT1-transporters in rat BBB was
confirmed with L-leucine, which is an endogenous substrate for
the  LAT1  (Duelli  et  al.,  2000).  The  PA  product  of  0.2  µCi/mL
[14C]L-leucine was determined to be 0.02059 ± 0.00323  mL/s/g
(mean ± s.d., n=5). The PA product was also determined using 5
°C perfusion medium with PA product of 0.0037 ± 0.00023
mL/s/g (mean ± s.d., n=3), suggesting that the uptake of L-
leucine in the in situ rat brain perfusion test method was carrier-
mediated, since the carrier-mediated uptake is reduced when
the temperature is lowered (Kageyama et al., 2000). In addition,
the determination of cerebrovascular LAT1 functional
expression was carried out with competition assay by perfusing
[14C]L-leucine (0.2 µCi/mL) with 2 mM concentration of another
known LAT1 substrate, L-phenylalanine (Killian and Chikhale,
2001). This co-perfusion resulted in almost complete inhibition
(99%) of [14C]L-leucine brain uptake, thereby demonstrating
functional expression of cerebrovascular LAT1, which is in
agreement with the literature (Killian and Chikhale, 2001).
5.2.4 Determination of the brain uptake mechanism for
prodrugs
The ability of the prodrugs to bind into LAT1 was studied with
the in situ rat brain perfusion technique. In the presence of 70
µM L-tyrosine-ketoprofen prodrug or 90 µM L-lysine-ketoprofen
prodrug,  the  [14C]L-leucine PA product was significantly
decreased from 0.02059 ± 0.00323  mL/s/g (mean ± s.d., n=5) to
0.000317 ± 0.000136 mL/s/g (mean ± s.d., n=3) (98.5% inhibition)
and 0.00426 ± 0.00019 mL/s/g (mean ± s.d., n=3) (79.3%
inhibition), respectively. This is a clear evidence of significant
85
binding of the prodrugs to the LAT1 (Fig. 5.2). To further study
the binding kinetics of the prodrugs to LAT1, the PA product of
[14C]L-leucine was determined after perfusing rat brain first with
the  prodrugs  for  30  s,  followed  by  washing  the  prodrug  from
the brain capillaries with 30 s perfusion of prodrug-free
perfusion medium and finally perfusing the rat brain with 0.2
µCi/mL [14C]L-leucine for 30 s. The PA product of [14C]L-leucine
had recovered, indicating that the binding of L-tyrosine-
ketoprofen prodrug and L-lysine-ketoprofen prodrug  to the
LAT1 is reversible (Fig. 5.2).
To support the proposed structural requirements for LAT1
substrates reported by (Uchino et al., 2002) we synthesized two
ketoprofen prodrugs with phenylalanine promoiety (2 and 3)
and two prodrugs with leucine promoiety (4 and 5). Ketoprofen
was conjugated with the carboxyl group by diethylester linker
or the amino group to remove the zwitter ionic properties of the
amino acids that are necessary for LAT1 recognition. The 100%
PA product of [14C]L-leucine was determined after 30 s
perfusion of 0.2 µCi/mL [14C]L-leucine solution. In a competition
study  [14C]L-leucine  (0.2  µCi/mL)  was  co-perfused  with  70  µM
concentration  of  the  prodrugs  for  30  s.  In  the  presence  of
phenylalanine and leucine prodrugs, the PA product of [14C]L-
leucine was 0.02815 ± 0.0059 (2), 0.01910 ± 0.0063 (3), 0.02117 ±
0.0072 (4), 0.02655 ± 0.0018 (5) (mean ± s.d., n=2). This indicates
that none of these four prodrugs was able to bind to LAT1,
which is in correlation with the literature (Uchino et al., 2002).
Therefore, our results support the previous reports that the
potential substrate should have positively charged amino group,
a negatively charged carboxyl group and a hydrophobic side
chain. As none of the phenylalanine or leucine prodrugs was
able to bind to LAT1, these prodrugs were not studied further.
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Figure 5.2. Mechanism of rat brain uptake of the prodrugs. The
PA product of  0.2 µCi/mL [14C]L-leucine in absence or presence
of 1. The control PA product 0.02059 ± 0.00323 mL/s/g (mean ±
s.d., n=5) is decreased to 0.000317 ± 0.000136 mL/s/g in the
presence of 70 µM 1 (98.5% inhibition). The uptake of [14C]L-
leucine is recovered after washing the prodrug from the brain
capillaries demonstrating the PA product of  0.01902 ± 0.0058
mL/s/g. The data is presented as mean ± s.d. (n=3). An asterisk
denotes a statistically significant difference from the respective
control (***P<0.001, followed by Dunnett t-test).
After demonstrating affinity for LAT1, the in situ rat brain
uptake of the prodrug was determined to be concentration
dependent in the dose range from 0 µM to 138 µM for 1 (Fig.
5.3), indicative of transporter-mediated uptake. In addition, the
brain uptake of 64 µM 1 was 0.846 ± 0.069 pmol/mg/min and
addition of 2 mM 2-aminobicyclo-(2, 2, 1)-heptane-2-carboxylic
acid (BCH), a specific LAT1 substrate (Kageyama et al., 2000), to
the perfusion medium significantly decreased the brain uptake
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to 0.362 ± 0.065 pmol/mg/min (Fig. 5.4), evidence that the uptake
was LAT1-mediated (Fig. 5.4).
Figure 5.3. Kinetics of the rat brain uptake of the prodrugs. Km
and  Vmax are 22.49 ± 9.18 µM and 1.41 ± 0.15 pmol/mg/min
(mean ± s.d., n=3) for 1.
Figure 5.4. The brain uptake of 64 µM 1. The brain uptake of 1
decreased from 0.846 ± 0.069 pmol/mg/min to 0.362 ± 0.065
pmol/mg/min  in  the  presence  of  2  mM  BCH.  The  data  is
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presented as mean ± s.d. (n=3). The decrease of the uptake is
statistically significant (***P=0.001, t-test).
5.2.5 Capillary depletion analysis
Capillary depletion analysis of brain samples from perfused
brain showed that 1 is present in the supernatant fraction which
consists of brain parenchyma (Table 5.1). The concentration of 1
in the endothelial cell enriched pellet fraction was below the
lower limit of detection. However, since the uptake of 1
determined from the whole brain is higher compared to brain
parenchyma, a fraction of 1 is  probably  captured  into  the
endothelial cells.
Table 5.1. Capillary depletion analysis after 60 s perfusion of 1
prodrug with 85 µM concentration, followed by washing the
prodrug from the capillaries with 30 s perfusion.
Right cerebrum Vd
(mL/g)
Whole brain 0.0123 ± 0.0016
Supernatant 0.0118 ± 0.0008
Pellet -a
mean ± s.d., n=3, a below lower limit of detection
5.2.6 Data Analyses
Statistical differences between groups were tested using one-
way ANOVA, followed by two-tailed Dunnett t-test (Fig. 5.2). In
figure 5.3, two tailed independent samples t-test was used.
P<0.05 was considered as statistically significant. Data analyses
for the dose-uptake curve (Fig. 5.4) were calculated as nonlinear
regressions using GraphPad Prism 4.0 for Windows.  The
normality of the data was tested using Shapiro-Wilk test. All
statistical analyses were performed using SPSS 14.0 for
Windows.
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5.3 CONCLUSIONS
In the present study we were able to demonstrate that amino
acid prodrugs of ketoprofen are able to cross the BBB LAT1-
mediatedly. In addition, our results supported the earlier
proposal that the parent drug has to be conjugated with the
amino acid promoiety from the side chain in order to maintain
the  affinity  for  LAT1.  One  of  the  synthesized  prodrugs, 1, was
able to utilize LAT1 for brain permeation. Our results show that
the prodrug is able to significantly inhibit the LAT1-mediated
uptake of L-leucine, the brain uptake of the prodrug was
saturable and the uptake was inhibited by LAT1 substrate.
Although 1 was too labile to be tested in vivo and the present
study evaluated only the brain uptake of this ketoprofen
prodrug in situ, the strategy may offer a potential way to
achieve shuttling of other small molecular weight CNS drugs
especially with low BBB permeation, into the brain.
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6 Brain uptake and intra-
cerebral distribution of
ketoprofen-amino acid
prodrugs
Abstract. The  efficient  brain  uptake  of  amino  acids  as  well  as
some CNS drugs via LAT1 suggests that the transporter could
also be used to target prodrugs into the brain. A hydrophilic
drug, ketoprofen, that is not a substrate for LAT1 was chosen as
a model compound. L-lysine-ketoprofen amide showed affinity
for LAT1. The mechanism and the kinetics of the brain uptake of
the prodrug were determined with in situ rat brain perfusion
technique. The brain uptake of the prodrug was found to be
concentration dependent. In addition, LAT1 inhibitor
significantly decreased the brain uptake of the prodrug.
Furthermore, the ability to deliver ketoprofen into the brain ICF
in vivo was evaluated for L-lysine-ketoprofen amide. The L-
lysine prodrug was able to deliver ketoprofen into the intra-
cellular compartment of brain cells. Therefore, our results show
that the amino acid prodrug approach can achieve brain uptake
of small molecular weight drugs in vivo via LAT1.
Adapted with of permission Elsevier B.V. from: Gynther M., Laine K.,
Ropponen J., Leppänen J., Lehtonen M., Kauvosaari J., Jalkanen A., Forsberg
M., Rautio J.: Brain uptake of ketoprofen-lysine prodrug in rats. International
Journal of Pharmaceutics 399: 121-128, 2010. © 2010 Elsevier B.V. All rights
reserved.
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6.1 INTRODUCTION
BBB permeability and the non-specific interaction with brain
tissue are important factors for uptake optimization
(Summerfield et al., 2006). In cases where the site of action is
inside the cell, the cellular uptake of drugs is as important as the
BBB permeability (de Lange and Danhof, 2002). One attractive
approach to achieve good BBB penetration and low brain non-
specific tissue binding, without losing the pharmacological
activity, is to utilize the prodrug approach (Rautio et al., 2008).
The  properties  of  a  drug  molecule  can  be  altered  in  a  bio-
reversible manner by conjugating the drug with a suitable
promoiety. Traditionally, attempts have been made to overcome
the poor brain uptake of CNS drugs by increasing the
lipophilicity of the drug with a lipophilic promoiety. Increasing
the lipophilicity of a poorly permeable drug molecule often
leads to an increase in BBB permeability (Summerfield et al.,
2006; Summerfield et al., 2007). However, at same time, the
increased lipophilicity may increase accumulation of the drug in
peripheral tissues. Therefore, the percentage of the given dose
that gains the access into the brain in vivo may  actually  be
decreased. In addition, the binding to plasma protein is often
increased due to increased lipophilicity, which may decrease the
brain uptake. On the other hand, the lowering of the
lipophilicity  of  highly  tissue  bound drugs  often  results  in  poor
BBB permeability. Due to the complex role of the drug
lipophilicity in brain penetration, the traditional prodrug
approach, which deals with the hydrophilicity and lipophilicity
of the drugs, is often not suitable and instead, a more
sophisticated prodrug approach is needed.
Several specific endogenous influx transporters e.g. LAT1 have
been identified on the brain capillary endothelial cells which
form the BBB. LAT1 is expressed on the luminal and abluminal
membranes of the capillary endothelial cells and it efficiently
transports neutral L-amino  acids  (e.g., phenylalanine and
leucine) into the brain. Amino acid transporters are also
expressed in the neuronal and other cells in the brain
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parenchyma (Boado et al., 1999; Duelli et al., 2000). The
exploitation  of  the  LAT1 with  a  prodrug  approach  could  be  an
innovative way to enhance BBB permeation properties (Sakaeda
et al., 2001; Killian et al., 2007; Gynther et al., 2008) and improve
drug uptake into the brain intracellular compartment (Su et al.,
1995; Wang and Welty, 1996) without increasing non-specific
tissue binding. In addition, if one could achieve selective release
of  the  active  drug  in  the  target  tissue,  this  would  result  in  a
reduced plasma concentration of the drug and fewer peripheral
effects.
The  aim  of  the  study  was  to  design  and  synthesize  an  amino
acid prodrug of ketoprofen and to evaluate its ability to cross
the BBB via LAT1. The mechanism of brain uptake of the
prodrug was determined with in situ rat brain perfusion
technique. In addition, the ability deliver ketoprofen into the
brain ICF in vivo was  determined.  For  the in vivo brain uptake
evaluation i.v. bolus injection method was used. Furthermore,
the distribution of the prodrug inside the brain parenchyma was
evaluated.
6.2 RESULTS AND DISCUSSION
6.2.1 Design of the prodrug
L-Lysine was selected as the promoiety because the amine
functional group in the side chain permits the formation of
biodegradable linkage between this amino acid and ketoprofen.
L-Lysine is not a LAT1 substrate itself because of the hydrophilic
amino group in the side chain. However, it was hypothesized
that by conjugating the amino group with ketoprofen via an
amide bond, the prodrug formed would function as a LAT1
substrate since the hydrophilic amino group had been removed.
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Figure 6.1. Chemical structure of ketoprofen-L-lysine amide (6).
6.2.2 Chemical and enzymatic stability of the prodrugs
The L-lysine-ketoprofen prodrug (6) was stable in aqueous
solutions for two months. Therefore, the prodrug demonstrated
sufficient chemical stability in aqueous solutions for further
evaluation. If the target for a prodrug design is the site-selective
drug  delivery  to  the  CNS,  the  prodrug  must  not  only  be
delivered to its intended site of action, but its bioconversion
should also be selective (Anderson, 1996). 6 did not undergo
bioconversion in rat serum or tissue homogenates in vitro.
6.2.3 Determination of the brain uptake mechanism for
prodrugs
The ability of the prodrugs to bind into LAT1 was studied with
the in situ rat brain perfusion technique. In the presence of 90
µM L-lysine-ketoprofen prodrug, the [14C]L-leucine PA product
was significantly decreased from 0.02059 ± 0.00323  mL/s/g
(mean ± s.d., n=5) to 0.00426 ± 0.00019 mL/s/g (mean ± s.d., n=3)
(79.3% inhibition). This is a clear evidence of significant binding
of the prodrug to the LAT1 (Fig. 6.2). To further study the
binding kinetics of the prodrug to LAT1, the PA product of
[14C]L-leucine was determined after perfusing rat brain first with
the prodrug for 30 s, followed by washing the prodrug from the
brain capillaries with 30 s perfusion of prodrug-free perfusion
medium and finally perfusing the rat brain with 0.2 µCi/mL
[14C]L-leucine  for  30  s.  The  PA  product  of  [14C]L-leucine had
recovered, indicating that the binding of L-lysine-ketoprofen
prodrug  to the LAT1 is reversible (Fig. 6.2).
95
Figure 6.2. Mechanism of rat brain uptake of the prodrugs. The
PA product of  0.2 µCi/mL [14C]L-leucine in absence or presence
of 6. The control PA product 0.02059 ± 0.00323 mL/s/g (mean ±
s.d., n=5) is decreased to 0 0.00426 ± 0.00019 mL/s/g in the
presence of 90 mM 6 (79.3 % inhibition). The uptake of [14C]L-
leucine is recovered after washing the prodrug from the brain
capillaries demonstrating the PA product of  0.02084 ± 0.0031
mL/s/g for 6. The data is presented as mean ± s.d. (n=3). An
asterisk denotes a statistically significant difference from the
respective control (**P<0.01, one-way ANOVA, followed by
Dunnett t-test).
After demonstrating affinity for LAT1, the in situ rat brain
uptake of the prodrug was determined to be concentration
dependent in the dose range from 0 to 400 µM for 6 (Fig. 6.3),
indicative of transporter-mediated uptake. In addition, the brain
uptake of 25 µM 6 was  0.068  ±  0.000  pmol/mg/min  which
significantly decreased to 0.011 ± 0.020 pmol/mg/min after
addition of 2 mM L-phenylalanine,  a LAT1 substrate
(Kageyama et al., 2000), to the perfusion medium, evidence that
the uptake was LAT1-mediated (Fig. 6.4).
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Figure 6.3. Kinetics of the rat brain uptake of the prodrugs. Km
and  Vmax are 231.6 ± 60.4 µM and 1.50 ± 0.20 pmol/mg/min
(mean ± s.d., n=3) for 6.
Figure 6.4. The brain uptake of 25 µM 6. The brain uptake of 6
was 0.068 ± 0.000 pmol/mg/min which significantly decreased to
0.011 ± 0.02 pmol/mg/min after addition of 2 mM L-
phenylalanine. The data is presented as mean ± s.d. (n=3). The
decrease of the uptake is statistically significant (***P=0.001, t-
test).
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6.2.4 Ketoprofen-lysine amide is able to cross rat BBB in vivo
and is rapidly distributed from the brain extracellular
compartment
Encouraged by the in situ results, we determined the ability of 6
cross the BBB in vivo and compared its uptake to that of
ketoprofen. 0.2 mL of 30 mM (0.6 µmol) 6 or ketoprofen solution
was administered into the left jugular vein in rats. Samples were
collected with microdialysis probes from femoral vein and
striatum for 300 min: first at 10 min intervals for 60 min and
then at 20 min intervals. 6 could be detected from the brain ECF,
evidence that 6 is able to cross the BBB in vivo. The area under
the concentration curve for unbound drug (AUCu 10-300 min) in
brain ECF and plasma was determined for ketoprofen, 6, and
ketoprofen released from 6 (Table 6.2). While the apparent
maximum concentrations of 6 in  both  brain  and  blood  were
achieved rapidly, this was followed by a rapid distribution. In
contrast, ketoprofen achieved the apparent maximum
concentration in the brain slower (Fig. 6.5 a and b). The high free
concentration of 6 compared to total plasma concentration
suggests that 6 is not highly bound to plasma proteins. This was
confirmed by measuring the free fraction (fu,plasma) of ketoprofen
and 6 in rat plasma in vitro (Table 6.1).  However, the fu,plasma of
ketoprofen after its administration is approximately 60-fold
higher compared to the fu,plasma of ketoprofen released from 6.
The in vitro fu,plasma data is consistent with the ketoprofen in vivo
data. Therefore, it is possible that the lower fu,plasma of ketoprofen
released from 6 is an artifact caused by analytical difficulties due
to low ketoprofen concentrations in rat plasma. However, it is
now clear that 6 is able to penetrate the brain, but it was still
unclear why 6 is  so  rapidly  eliminated  from the  ECF.  After  i.v.
injection of 6 only a small concentration of released ketoprofen
was detected in plasma and the levels were barely detectable in
ECF (Table 6.1), indicating that the rapid elimination of 6 from
the ECF is not due to metabolism of 6.
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Figure 6.5. In vivo pharmacokinetics and brain uptake of 6 and
ketoprofen after i.v. bolus injection. (A) Free concentration of 6
and ketoprofen in rat blood after 6 µmol i.v. bolus injection of 6
or ketoprofen (B). Free concentration of 6 and ketoprofen in rat
brain ECF after 6 µmol i.v. bolus injection of 6 or ketoprofen. (C)
The plasma concentration of 6, ketoprofen released from 6 and
ketoprofen after administration of 6 or ketoprofen. (D) The brain
concentration of 6, ketoprofen released from 6 and ketoprofen
after administration of 6 or ketoprofen. The concentrations are
presented as mean ± s.e.m (n=3-7).
6.2.5 Ketoprofen-lysine amide is actively transported into the
brain cells
The microdialysis results indicated that there was either active
efflux of 6 from  brain  to  blood,  or  active  influx  from  ECF  to
brain cells. In addition, high non-specific binding into the brain
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tissue may also have accounted for the rapid decrease in the
ECF concentrations. In an attempt to elucidate which of these
mechanisms was involved, the concentrations of 6 and
ketoprofen were determined from whole brain tissue and blood
after an i.v. bolus injection of 6 or ketoprofen (Fig. 6.5 c and d).
After the injection, the rats were sacrificed at specific time points
ranging from 10 to 300 min. Blood and brain samples were
analyzed for 6 and ketoprofen concentrations (Table 6.1). The
results support the proposal that 6 is transported into the brain.
In addition, the results indicate that ketoprofen is released from
6 within the brain tissue. When whole tissue results are
combined in vitro to  the  result  acquired  from  the  microdialysis
studies, the distributions of 6 and ketoprofen inside the BBB, the
value of Vu,brain, can be determined  (Table 6.1). The higher Vu,brain
of 6 compared to that of ketoprofen indicates that 6 is rapidly
removed from the ECF into the cells, and not effluxed into the
blood circulation. However, the high Vu,brain may also suggest
that 6 is highly bound non-specifically within the brain tissue,
which is not desirable. Therefore, the free fractions in brain
tissue of 6 and ketoprofen were determined in vitro (Table 6.1). 6
and ketoprofen were found to have quite similar free fractions
in brain tissue, indicating that the larger Vu,brain of 6 is not due to
non-specific binding to brain tissue. In addition, the
concentration ratio of unbound drug between ECF and ICF was
calculated (Table 6.1). Previously, uptake of 6 across  the  BBB
was shown to be LAT1-mediated in the in situ experiments.
Furthermore, the PSA of 6 is  109.5 Å2, which is higher than the
proposed maximum PSA of molecules that can readily penetrate
cell membrane via passive diffusion (Pajouhesh and Lenz, 2005).
Therefore, there is significant body of evidence supporting the
proposal that uptake of 6 into the brain cells is transporter-
mediated.
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6.2.6 Ketoprofen-lysine amide is able to release the parent
drug at the site of action
The results indicating, that 6 is able to cross the BBB via LAT1
and is subsequently actively transported into brain cells in vivo,
encouraged us to compare the abilities of 6 and  ketoprofen  to
deliver unbound ketoprofen into the brain ICF. The area under
the concentration curve of unbound drug in the ICF (AUCu,cell)
was determined for ketoprofen, 6 and ketoprofen released from
6 (Table 6.1). The AUCu,cell values of ketoprofen and ketoprofen
released from 6 were almost identical. However, at 300 min
there was still 6 present in the ICF, which probably is able to
release more ketoprofen at the later time-points. In addition, the
distribution of ketoprofen originating from 6 and ketoprofen
between ICF and ECF was calculated (Table 6.1). Since
ketoprofen is released from 6 intracellularly, the ICF-to-ECF
ratio was significantly (135 times) higher for 6 as compared to
ketoprofen administration. Furthermore, it has been reported
that the relationship between brain unbound ECF concentration
and unbound plasma concentration is the most useful parameter
in the evaluation of the extent of the brain drug delivery
(Hammarlund-Udenaes et al., 2008; Liu et al., 2008). However,
when there is active transport present from ECF to ICF, it cannot
be assumed that the ECF and ICF concentrations are equal. In
addition, the target protein of ketoprofen resides within the cell
(Spencer et al., 1998; Teismann et al., 2003). Therefore, the more
appropriate parameter is the unbound concentration ratio
between ICF and plasma. The results show that the
concentration ratio of ketoprofen when 6 is administered is 363
times larger than that obtained after ketoprofen administration.
This is due to low ketoprofen concentration released from 6 in
plasma and the better brain uptake of 6 than can be achieved
with ketoprofen. However, as the AUCu,cell of L-lysine-
ketoprofen prodrug is not significantly higher compared to that
of ketoprofen, the 363-fold difference in unbound ICF-to-plasma
ratio has to be due to lower ketoprofen concentrations in
plasma. The lower plasma concentration of ketoprofen after 6
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administration is due to higher volume of distribution (Vd) and
faster elimination of 6 from central compartment, compared to
ketoprofen. The Vd and  CL were calculated for both 6 and
ketoprofen after i.v. bolus injection. The Vd and CL were 0.046 L
and  0.017  L/min  for 6 and,  0.028  L  and  0.001  L/min  for
ketoprofen, respectively.
6.2.7 Data Analyses
Statistical differences between groups were tested using one-
way ANOVA, followed by two-tailed Dunnett t-test (Fig. 6.2). In
figure 6.3, two tailed independent samples t-test was used.
P<0.05 was considered as statistically significant. Data analyses
for the dose-uptake curve (Fig. 6.4) were calculated as nonlinear
regressions using GraphPad Prism 4.0 for Windows. The area
under the concentration curves were calculated as 10-300 min,
because there were too few data points in the elimination phase
to be extrapolated as 0-∞. The area under the concentration
curves were calculated with GraphPad Prism 4.0 for Windows.
The normality of the data was tested using Shapiro-Wilk test.
All statistical analyses were performed using SPSS 14.0 for
Windows.
6.3 CONCLUSIONS
In the present study we were able to demonstrate that amino
acid prodrugs of ketoprofen are able to cross the BBB LAT1-
mediatedly. In addition, our results supported the earlier
proposal that the parent drug has to be conjugated with the
amino acid promoiety from the side chain in order to maintain
the affinity for LAT1. The synthesized prodrugs 6,  was  able  to
utilize LAT1 for brain permeation. Our results show that 6 was
able to significantly inhibit the LAT1-mediated uptake of L-
leucine, the brain uptake of the prodrug was saturable and the
uptake was inhibited by LAT1 substrate. According to in situ
brain uptake studies 1 has higher affinity for LAT1 compared to
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6 (Fig. 5.2 and 6.2). This may be due to higher lipophilicity of 1
or to the 3D structure of the prodrugs. However, 1 was too labile
to be tested in vivo. Therefore, the in vivo brain uptake was
determined only for 6.
In the in vivo studies we were able to demonstrate that 6 is able
to cross the BBB. In addition, a large fraction of the prodrug was
taken up by brain cells, where ketoprofen was released. In fact, 6
acts rather similarly as another LAT1 substrate, gabapentin, a
drug which has low lipophilicity and is extensively distributed
into brain cells (Friden et al., 2007). In addition, several authors
have reported that gabapentin is actively transported into
neuronal cells (Su et al., 1995; Wang and Welty, 1996). The high
free fraction of 6 in plasma and the rapid cellular uptake into the
brain cells indicate that there is a steep concentration gradient
across the BBB, which enables LAT1-mediated uptake of 6
across the BBB. In addition, 6 was rapidly removed from ECF
into ICF where a significant amount of ketoprofen was released.
Furthermore, the distribution of unbound ketoprofen at the
active site compared to plasma concentration was 363 times
larger when 6 was administered compared to the corresponding
situation with ketoprofen. This is probably due to distribution of
6 into peripheral tissues. However, the concentrations of 6 and
ketoprofen should be determined from peripheral tissues to
confirm this. In addition, the pharmacokinetics of 6 could be
elucidated more using i.v. infusion to achieve steady state.
Although the present study evaluated only the brain uptake of
this ketoprofen prodrug, the strategy may offer a potential way
to achieve shuttling of other small molecular weight CNS drugs
especially with low BBB permeation, into the brain. In
conclusion, conjugating ketoprofen with L-lysine, LAT1-
mediated brain uptake and drug distribution into the ICF of
brain parenchyma can be achieved.
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7 Glucose promoiety
enables GluT-1 -mediated
brain uptake of ketoprofen
and indomethacin
prodrugs
Abstract. GluT1  is  present  both  on  the  luminal  and  the
abluminal membrane of the endothelial cells forming the BBB.
One attractive approach to utilize GluT1 for enhanced brain
drug delivery of CNS drugs is to conjugate an endogenous
transporter substrate to the active drug molecule to utilize the
prodrug approach. In the present study, ketoprofen and
indomethacin were conjugated with glucose and the brain
uptake mechanism of the prodrugs was determined with the in
situ rat brain perfusion technique. Two of the four prodrugs
were able to significantly inhibit the GluT1-mediated uptake of
glucose, thereby demonstrating affinity to the transporter.
Furthermore,  the  prodrugs  were  able  to  cross  the  BBB  in  a
temperature dependent manner, suggesting that the brain
uptake of the prodrugs is carrier-mediated. These results
indicate that glucose prodrugs are able to cross the BBB via
GluT1.
Adapted with permission of the American Chemical Society from: Gynther
M.,  Ropponen J.,  Laine  K.,  Leppänen J.,  Haapakoski  P.,  Peura  L.,  Järvinen  T.,
Rautio J.: Glucose Promoiety Enables Glucose Transporter Mediated Brain
Uptake  of  Ketoprofen  and  Indomethacin  Prodrugs  in  Rats.  Journal  of
Medicinal Chemistry 52: 3348-3353, 2009. © 2009 the American Chemical
Society. All rights reserved.
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7.1 INTRODUCTION
GluT1 is present both on the luminal and the abluminal
membrane of the endothelial cells forming the BBB (Farrell,
Pardridge, 1991). GluT1 transports glucose and other hexoses
and has the highest transport capacity of the carrier-mediated
transporters present at the BBB, being therefore an attractive
transporter for prodrug delivery (Anderson, 1996). Several in
vitro studies have been performed with different drug molecules
in order to determine the ability of glycosyl derivatives to bind
to GluT1. In addition, systemically delivered glycosyl
derivatives of 7-chlorokynurenic acid, L-dopa, and dopamine
have been shown to have pharmacological activity in the CNS of
rodents (Halmos et al., 1996; Battaglia et al., 2000; Bonina et al.,
2003; Fernandez et al., 2003). These previous studies have
indeed demonstrated that glucose conjugates can bind to GluT1
and that the derivatives are centrally available, but none of these
studies verified the ability of conjugates to cross the BBB via
GluT1.
The overall aim of the present study was to show with two
model compounds ketoprofen and indomethacin using in situ
rat brain perfusion technique, that GluT1 can be utilized to carry
non-substrate drugs into the brain by conjugating a drug
molecule to D-glucose with bioreversible linkage. Four glucose
prodrugs synthesized and studied are ketoprofen-glucose
produg  (7), indomethacin-glucose prodrug (8), indomethacin-
glycolic acid-glucose prodrug (9) and indomethacin-lactic acid-
glucose prodrug (10) (Fig. 7.1).
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Figure 7.1. Chemical structures of ketoprofen prodrug 7 and
indomethacin prodrugs 8, 9 and 10.
7.2 RESULTS AND DISCUSSION
7.2.1 Design of the prodrugs
Ketoprofen and indomethacin were chosen as model
compounds because they are easy to detect with UV-detector
and  they  have  a  carboxyl  group,  which  makes  it  easy  to
conjugate with D-glucose.  In addition, it has been proposed that
non-steroidal anti-inflammatory drugs may have some
therapeutic effects in CNS disorders, such as Alzheimer`s
disease. The molecular weights of ketoprofen and indomethacin
are 254 Da and 357 Da, respectively. Therefore, the ability of
GluT1 to transport different sized molecules can be evaluated.
According  to  the  GluT1  model  published  by  (Mueckler,
Makepeace, 2008) the hydroxyl group of glucose situated at the
carbon 6-position goes into a hydrophobic pocket in the
transporter protein substrate binding site. In addition, the
hydroxyl  group  at  the  carbon  6-position  does  not  form  a
hydrogen bond with the transporter that would be crucial for
the affinity. Fernandez et al., (2000) synthesized several glycosyl
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derivatives of dopamine and tested the affinity of the prodrugs
to GluT1 in human erythrocytes. Dopamine was linked to
glucose with different linkers at the carbon 1-, 3-, and 6-
positions of glucose. The results of glucose uptake inhibition
showed that the glucose derivatives that were conjugated at
position 6 had the best affinity for GluT1. Therefore, the
hydroxyl group at the carbon 6-position is likely the most
potential functional group to which to attach the drug molecule
in order to maintain the affinity of the glucose conjugate for
GluT1.
7.2.2 Chemical and enzymatic stability of prodrugs
The degradation of prodrugs 7 - 10 was studied in aqueous
buffer solution of pH 7.4 at 37 °C. The degradation of 7 and 8
followed pseudo-first-order kinetics with the half-lives of 88.6 ±
0.0 and 73.4 ± 1.6 hours (mean ± s.d., n=2), respectively (table
6.1). Therefore, both 7 and 8 demonstrated sufficient chemical
stability in aqueous solutions for further evaluation. However, 9
and 10 were degraded with the half-lives of 3.0 ± 0.2 and 9.5 ±
0.0 hours (mean ± s.d., n=2). Therefore, 9 and 10 are not stable
enough to be tested with in situ rat brain perfusion technique.
7 was susceptible to enzymatic hydrolysis as it was
quantitatively cleaved to ketoprofen and glucose in 20% rat
brain homogenate and in 50% rat liver homogenate. The
enzymatic hydrolysis followed pseudo-first-order kinetics, the
half-lives being 43.5 ± 3.6 and 8.6 ± 0.6 minutes (mean ± s.d., n=3)
in brain homogenate and liver homogenate, respectively.
Therefore, 7 undergoes bioconversion to ketoprofen and glucose
in the brain tissue. However, 7 is also highly susceptible to
enzymatic hydrolysis in liver which may compromise its
effective brain drug delivery in vivo. Enzymatic hydrolysis
studies of 8 in neither brain nor liver homogenate resulted in the
formation of indomethacin which makes the prodrug not
suitable for brain delivery. Since indomethacin was not released
from the prodrug, the hydrolysis products and the half-life of 8
were not identified. In an attempt to solve the problem, we
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synthesised two prodrugs (9 and 10) with glycolic acid and
lactic acid linker group between glucose and indomethacin.
However, these were not stable enough to be tested.
Although 8 did not release the parent drug in brain tissue, it is
reasonable to determine the brain uptake of 8. Since 8 has higher
molecular weight than 7, determining the uptake mechanism of
both prodrugs may give more insight into the GluT1 ability to
transport molecules across the BBB.
Table 7.1. Molecular weight, hydrolysis rates in phosphate
buffer solution and polar surface area of the prodrugs.
Prodrug Molecular weight
(g/mol)
t1/2 (h)  37 °C
phosphate buffer
(pH 7.4)
Polar surface
area (Å2)
7 416 88.5 ± 0.0 133.52
8 519 40.5 ± 2.5 145.99
9 577 3.0 ± 0.2 172.29
10 591 9.5 ± 0.0 172.29
mean ± s.d., n=2
7.2.3 Determination of the brain uptake mechanism for
prodrugs
The in situ rat brain perfusion technique has not been previously
used to determine the brain uptake of glycosyl conjugates.
Therefore, the suitability of the technique for glycosyl conjugate
uptake determination was studied by confirming the presence
of functional GluT1-transporters in rat BBB with [14C]D-glucose,
which is an endogenous substrate for the GluT1 (Farrell,
Pardridge, 1991). The uptake of molecules across the BBB was
quantified by determining the permeability-surface area (PA)
product.  The  PA  product  of  0.2  µCi/mL  [14C]D-glucose was
determined to be 0.0042 ± 0.0002 mL/s/g (mean ± s.d., n=4) (Fig.
7.2). In addition, the determination of cerebrovascular GluT1
functional expression was carried out with a competition assay
by  perfusing  [14C]D-glucose  (0.2  µCi/mL)  with  20  mM
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concentration of glucose. This co-perfusion resulted in a brain
uptake of 0.0011 ± 0.0003 mL/s/g (mean ± s.d., n=3) (73.8%
inhibition) of [14C]D-glucose, thereby demonstrating functional
expression of cerebrovascular GluT1. The PA product was also
determined using 5 °C perfusion medium which resulted in
76.2% inhibition of the PA product of [14C]D-glucose  to  0.001  ±
0.0003 mL/s/g (mean ± s.d., n=3). This further suggests that the
uptake of [14C]D-glucose  in  the in situ rat brain perfusion test
method was carrier-mediated, since this type of uptake is
reduced when the temperature is lowered (Kageyama et al.,
2000; Gynther et al., 2008). However, the uptake of [14C]D-
glucose is not completely inhibited at low temperature, which
suggests that some activity of GluT1 is still present at the BBB.
There is also the possibility that a part of the uptake of [14C]D-
glucose is due to passive diffusion. However, 80 µM 8 is able to
inhibit the [14C]D-glucose uptake almost completely (96.7%
inhibition), which indicates that there is no passive uptake of
[14C]D-glucose present at the BBB.
The ability of 7 and 8 to  bind  into  GluT1  was  studied  by  co-
perfusing increasing concentrations of the prodrugs with [14C]D-
glucose. The prodrugs were able to inhibit the uptake of [14C]D-
glucose in a concentration-dependent manner (Fig. 7.3). Non-
linear regression analysis was used to determine the half-
maximal inhibitory concentration (IC50) values of 7 and 8. The
IC50 values were 32.85 ± 8.17 µM for 7 and 0.71 ± 0.04 µM for 8,
which indicates that 7 has lower affinity for GluT1 compared to
8.
To further study the binding kinetics of  the prodrugs to GluT1,
the  PA  product  of  [14C]D-glucose was determined after
perfusing  rat  brain  first  with  the  prodrugs  at  80  µM  for  30  s,
followed by washing the prodrug from the brain capillaries with
30 s perfusion of prodrug-free perfusion medium and finally
perfusing the rat  brain with 0.2 µCi/mL [14C]D-glucose for 30 s.
This  resulted  in  the  PA  products  of  [14C]D-glucose 0.0033 ±
0.0001 mL/s/g and 0.0032 ± 0.0003 mL/s/g (mean ± s.d., n=3) for 7
and 8, respectively, indicating that the binding of 7 and 8 to the
GluT1 is reversible (Fig. 7.2).
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These results show that 8 has higher affinity for GluT1 than 7,
and both of the prodrugs have higher affinity for GluT1 than D-
glucose. This higher inhibition caused by the prodrugs
compared to D-glucose  could  be  due  to  the  higher  molecular
weight of the prodrugs. It is proposed that as the substrate binds
to the GluT1 binding site, the transporter protein cavity
occludes the bound substrate and then opens at the opposite
side of the membrane where the bound substrate can dissociate
(Blodgett, Carruthers, 2005). The sterical hindrance caused by
the higher molecular weight of the prodrugs could slow the
conformational change of the transporter, and as the
transporters are occupied by the prodrugs, the transporters are
not able to facilitate the uptake of [14C]D-glucose. Therefore, the
low IC50 values only suggest that the prodrugs are able to bind
to  GluT1  and  the  ability  cross  the  BBB  is  not  necessarily
achieved.
Figure 7.2.  Mechanism of 7 and 8 rat brain uptake. The PA
product  of  0.2  µCi/mL [14C]D-glucose in absence or presence of
D-glucose, low temperature, 7 or 8.  The  control  PA  0.0042  ±
0.0002 mL/s/g (mean ± s.d., n=4) is decreased to 0.0011 ± 0.0003
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(mean ± s.d., n=3) (73.8% inhibition) in the presence of 20 mM D-
glucose and to 0.001 ± 0.0003 mL/s/g (mean ± s.d., n=3) (76.2%
inhibition), when using 5 °C perfusion medium. The PA product
of  [14C]D-glucose decreased to 0.00103 ± 0.00014 mL/s/g (75.5%
inhibition) and 0.00014 ± 0.00005 mL/s/g (96.7% inhibition)
(mean ± s.d., n=3) after perfusing the brain with 7 and 8,
respectively. After washing 7 from the brain capillaries the PA
product of 0.2 µCi/mL [14C]D-glucose was 0.0033 ± 0.0001 mL/s/g
(mean ± s.d., n=3) and the PA product of 0.2 µCi/mL [14C]D-
glucose was 0.0032 ± 0.0003 mL/s/g (mean ± s.d., n=3) after 8 was
washed from the brain capillaries. An asterisk denotes a
statistically significant difference from the respective control
(***P<0.001, **P<0.01, *P<0.05, Brown Fortsythe, followed by
Dunnett T3-test).
Figure 7.3. Inhibition  of  0.2  µCi/mL [14C]D-glucose uptake by 7
and 8. IC50 values are 32.85 ± 8.17 µM and 0.71 ± 0.04 µM for 7
and 8, respectively. Data are mean ± s.d. (n = 2). IC50 values are
calculated with non-linear regression analysis, using GraphPad
Prism 4.0 for Windows.
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7.2.4 Brain uptake determination of the prodrugs
In  addition  to  determining  the  binding  of  the  prodrugs  to
GluT1, we also determined the brain uptake of the prodrugs
across the BBB.  The brain uptake of the prodrugs was
determined with the in situ rat brain perfusion technique using
150 µM and 60 s perfusion time (Fig. 7.4). The perfusion of 150
µM both 7 and 8 indeed resulted in detectable amounts of both
prodrugs in brain tissue. The brain uptake of 150 µM 7 was 1.33
± 0.18 pmol/mg/min (mean ± s.d., n=3), and an addition of 50
mM D-glucose  to  the  perfusion  medium  decreased  the  brain
uptake 61.4% to 0.513 ± 0.009 pmol/mg/min (mean ± s.d., n=3)
(Fig. 7.4). Finally, brain uptake of 7 was determined at 150 µM
concentration in a 5 °C perfusion medium. Lower temperature
decreased the uptake of 7 61.3% to 0.515 ± 0.065 pmol/mg/min
(mean ± s.d., n=3). The brain uptake of 7 was also determined
with 450 µM, 1000 µM, 3500 µM and 15000 µM concentrations
but the uptake was not saturable within this concentration range
(Fig. 7.5). It is possible that because of poor affinity of 7 for
GluT1 and high capacity of the transporter (Km value of D-
glucose uptake is 11 mM and Vmax is 1420 nmol/min/g),
(Anderson, 1996) the uptake did not become saturated, although
the uptake of 7 was mainly carrier-mediated. Another
explanation for the lack of uptake saturation could be that
passive diffusion of 7 is significant enough to hide the saturation
of GluT1-mediated uptake.
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Figure 7.4. The brain uptake of 7 and 8. The uptake of 7 with 150
µM concentration is 1.33 ± 0.18 pmol/mg/min and addition 50
mM D-glucose to the perfusion medium decreased significantly
(61.4% inhibition) the brain uptake to 0.513 ± 0.009
pmol/mg/min (mean ± s.d., n=3). 5 °C perfusion medium
decreased significantly the uptake of 7 to 0.515 ± 0.065
pmol/mg/min (mean ± s.d., n=3) (61.3% inhibition). The brain
uptake of 150 µM 8 was 1.993 ± 0.429 pmol/mg/min (mean ± s.d.,
n=3) and after the addition of 50 mM D-glucose to the perfusion
medium the uptake was 1.806 ± 0.353 pmol/mg/min (mean ±
s.d., n=3). The decrease of the perfusion medium temperature to
5 °C resulted in brain uptake of 0.599 ± 0.098 pmol/mg/min
(mean ± s.d., n=3) (69.9% inhibition).  An asterisk denotes a
statistically significant difference from the respective control
(**P<0.01, *P<0.05, one-way ANOVA, followed by Dunnett t-
test). Columns 150 µM 7 and 150 µM 8 were used as controls in
Dunnett t-test.
The brain uptake of 150 µM 8 was 1.993 ± 0.429 pmol/mg/min
(mean ± s.d., n=3) (Fig. 7.4) and after the addition of 50 mM D-
glucose to the perfusion medium the uptake was 1.806 ± 0.353
pmol/mg/min (mean ± s.d., n=3). The decrease of the perfusion
medium temperature to 5 °C resulted in brain uptake of 0.599 ±
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0.098 pmol/mg/min (mean ± s.d., n=3) (69.9% inhibition). The
uptake of 8 was slightly higher than the uptake of 7, and the
uptake was not decreased by addition of D-glucose in the
perfusion medium, unlike the uptake of 7. Since addition of D-
glucose did not affect the uptake of 8,  as uptake is either due to
passive diffusion or the affinity of 8 for GluT1 is much higher
than the affinity of D-glucose.
The passive diffusion of the prodrugs across the BBB is probably
limited, since the polar surface areas of the prodrugs are over 90
Å2 (Table 6.1) (Pajouhesh, Lenz, 2005). In addition, the uptake of
both prodrugs was significantly decreased by low temperature,
which indicates that the uptake of the prodrugs is carrier-
mediated. The low temperature could not inhibit the uptake of
the prodrugs entirely, which may indicate that the brain uptake
of the prodrugs is partly due to passive diffusion. However, the
uptake of [14C]D-glucose was not entirely inhibited by low
temperature and leaving some transporter activity present at the
BBB.  Therefore,  the  fraction  of  passive  diffusion  of  the  whole
brain uptake cannot be determined without using a non-
competing GluT1 inhibitor. As far we are aware, such an
inhibitor suitable for in situ rat brain perfusion does not exist.
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Figure 7.5. Relationship between concentration of the perfusion
medium and brain uptake of prodrug 7. The uptake of 7 was
1.33 ± 0.18, 3.55 ± 0.33, 7.78 ± 0.68, 20.77 ± 0.78 and 93.21 ± 5.51
pmol/mg/min (mean ± s.d., n=3) using 150 µM, 450 µM, 1000
µM, 3500 µM and 15000 µM concentrations, respectively.
7.2.5 Capillary depletion analysis
Capillary depletion analysis of brain samples from perfused
brain showed that the prodrugs are present in the supernatant
fraction which consists of brain parenchyma (Table 7.2). The
concentration of the prodrugs in the endothelial cell enriched
pellet fraction was below the lower limit of detection. However,
since the uptake of the prodrugs determined from the whole
brain is higher compared to brain parenchyma (supernatant), a
fraction of the prodrugs is captured into the endothelial cells.
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Table 7.2. Capillary depletion analysis after 60 s perfusion of 7
and 8 with 450 µM concentration, followed by washing the
prodrug from the capillaries with 30 s perfusion.
Right cerebrum   Vd
(mL/g)
7
Whole brain 0.0054 ± 0.0002
Supernatant 0.0050 ± 0.0006
Pellet a
8
Whole brain 0.0155 ± 0.0044
Supernatant 0.0135 ± 0.0052
Pellet a
mean ± s.d., n=3, a below lower limit of detection
7.2.6 Data Analyses
The results from the brain uptake experiments are presented as
mean ± s.d. of at least three independent experiments. Statistical
differences between groups were tested using Brown Fortsythe,
followed by Dunnett T3 –test (Fig. 7.2) and one-way ANOVA,
followed by two-tailed Dunnett t-test (Fig. 7.4). The normality of
the data was tested using Shapiro-Wilk test. The IC50 values
(Fig. 7.3) were determined by non-linear regression analysis
using GraphPad Prism 4.0 for Windows. All statistical analyses
were performed using SPSS 14.0 for Windows.
7.3 CONCLUSION
In this study, four glucose prodrugs were synthesized and their
ability to cross the BBB via GluT1 was determined with in situ
rat brain perfusion technique for two of the prodrugs (7 and 8).
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Both 7 and 8 demonstrated reversible concentration dependent
inhibition of brain uptake of the radiotracer [14C]D-glucose in the
in situ rat brain perfusion model, indicating that the prodrugs
bind to the GluT1. In addition, three factors strongly favour the
claim that the brain uptake of 7 and 8 is GluT1-mediated. First,
both prodrugs were able to cross the BBB and gain entry into the
brain tissue. Secondly, the uptake of 7 and 8 was decreased
significantly when 5 °C perfusion medium was used, indicating,
that the uptake is carrier-mediated. Furthermore, the high polar
surface areas of 7 and 8 indicate that passive diffusion across the
BBB is limited.
The uptake of 7 was decreased when 50 mM concentration of D-
glucose was added in to the perfusion medium. In addition, the
uptake of 7 did not become saturated even at 15 mM
concentration, which suggests that the affinity of 7 for Glut1 is
low and the capacity of the transporter is high. It is also possible
that passive diffusion of 7 is significant enough to obscure the
saturation of Glut1-mediated uptake. In the case of 8, the uptake
did  not  decrease  when  50  mM D-glucose was added into the
perfusion medium. However, the unspecific inhibition of GluT1
using a lowered temperature, suggests that the uptake of 8 is, at
least partly, GluT1-mediated. The lack of inhibition of 8 brain
uptake by 50 mM D-glucose indicates that the affinity of 8 for
the transporter is much higher than the affinity of D-glucose or
7. This hypothesis is further supported by the low IC50-value of
8.
These results indicate, that a hydrophilic drug can be attached to
the hydroxyl group of D-glucose at the carbon 6-position and
still maintain the affinity of the D-glucose promoiety for the
GluT1 transporter. However, glucose as a promoiety has several
limitations.  The  structure  of  glucose  limits  the  amount  of  drug
molecules that can be linked with it by biodegradable bonds. In
essence, only drugs that bear a carboxyl acid group can be
linked  without  a  linker/spacer  with  glucose  with  a  prodrug
bond. In addition, the stability of ester prodrugs in systemic
circulation might not be adequate for clinical use. Therefore this
prodrug technology demands further development before being
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fully  applicable  to  oral  drug  delivery.  In  summary,  drug
molecules as large as indomethacin, can be conjugated with D-
glucose and GluT1 is able to mediate the uptake of the conjugate
across the BBB into the brain parenchyma.
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8 General discussion
The need for new CNS drug targeting strategies is clear, because
a significant number of potential CNS drugs fail to achieve
efficient concentrations in their site of action. In this research, an
attempt was made to enhance the brain uptake of model drugs
by utilizing LAT1 and GluT1 transporters present at the BBB
with prodrug approach. This strategy is known in the literature.
However, there are many unresolved issues concerning the
usefulness of this strategy. First, the methods used to determine
the mechanism and extent of brain uptake have to be considered
carefully. Second, the distribution of the drug or prodrug in the
brain tissue is equally important as the systemic
pharmacokinetics. In this research an in situ rat brain perfusion
technique was used to evaluate the mechanism of BBB
permeation. In situ technique was chosen because it has
advantages over in vivo and in vitro methods.  The  most
important advantage is that the experimental conditions can be
easily manipulated. Therefore, saturable and temperature
sensitive processes, such as carrier-mediated brain uptake can
be evaluated. In addition, with the in situ technique, the ability
of the molecules to cross the functional BBB can be determined.
With an in vitro method, often only the ability to bind to
transporters can be determined. In in vitro permeation assays the
expression of transporters and tight junctions is not equivalent
to the in vivo situation. Although in situ technique is superior
when the mechanism of brain uptake is estimated, it cannot be
used to evaluate the extent of brain uptake. In addition, the
systemic pharmacokinetics cannot be determined. Therefore, the
i.v. single bolus injection method was used to determine the
ability of one of the prodrugs to cross the BBB in vivo. The
distribution beyond the BBB is as important as the ability cross
the BBB. Therefore, the distribution of unbound prodrug and
released parent drug was assessed with a combination of whole
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tissue concentrations, ECF concentrations and in vitro unbound
fraction in brain homogenate.
8.1 SUMMARY OF THE EVALUATION OF AMINO ACID
PRODRUGS
Two amino acid prodrugs were designed to meet requirements
for LAT1 substrates based on the LAT1 binding site model
which indicated that a potential LAT1 substrate should have a
positively charged amino group, a negatively charged carboxyl
group  and  a  hydrophobic  side  chain.  Both  prodrugs  were  able
to bind to LAT1 and cross the BBB via LAT1. We also designed
prodrugs, in which the parent drug was conjugated with the
amino acid by either the amino group or the carboxyl group
necessary for LAT1 recognition. The inability of these prodrugs
to inhibit LAT1 confirmed the requirements for LAT1
substrates.
An L-tyrosine prodrug of ketoprofen demonstrated significant
reversible inhibition of brain uptake of the radiotracer [14C]L-
leucine in the in situ rat brain perfusion model, indicating that
the prodrug binds to the LAT1. More importantly,  the prodrug
is able to cross the endothelial cells and penetrate into the brain
parenchyma and the brain uptake of the prodrug was both
concentration-dependent and saturable. The uptake of the
prodrug was also significantly decreased when 5 °C perfusion
medium was used indicating the brain uptake of the prodrug is
carrier-mediated. In addition, the LAT1 inhibitor BCH
significantly decreased the brain uptake of the prodrug. Overall,
these results strongly suggest that the rat brain uptake of the
prodrug is LAT1-mediated. Importantly, the prodrug is not only
recognized but also transported across the rat BBB by LAT1. In
the prodrug structure, L-tyrosine acts as a carrier that possesses
the essential structural features needed for LAT1-binding. The
systemic pharmacokinetics of the prodrug is unknown but the
ester bond between ketoprofen and L-tyrosine is probably
cleaved mostly by esterases present in the peripheral tissues.
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Therefore this prodrug technology demands further
development before being fully applicable to oral drug delivery.
To overcome the problem of rapid degradation of the bond
between the parent drug and the promoiety, a more stable
prodrug has to be designed. Instead of designing an ester
prodrug it was decided to try amide bond between the parent
drug and amino acid. However, LAT1 substrates have an
optimal structure for LAT1 binding. Therefore, the side chains
LAT1 substrates do not have suitable functional groups for the
formation of an amide bond with ketoprofen. However, there
are amino acids which are not LAT1 substrates themselves but
have suitable functional groups in their side chain. It was
hypothesized that by conjugating the hydrophilic functional
group of the side chain with the parent drug, the formed
prodrug would be a LAT1 substrate. This hypothesis was tested
by designing an L-lysine-ketoprofen amide prodrug. The L-
lysine-ketoprofen prodrug was able to cross the BBB by utilizing
LAT1. In addition, the prodrug was rapidly removed, probably
by active transporter, from brain ECF into ICF where ketoprofen
was released. Furthermore, the distribution of unbound
ketoprofen at the active site compared to plasma concentration
was 363 times larger when the prodrug was administered
compared to the corresponding situation with ketoprofen.
However, the prodrug was probably distributed into peripheral
tissues, because the plasma concentrations of the prodrug were
low. The most important results are that other amino acids than
LAT1 substrates can be used as promoieties and amino acid
prodrugs are able to deliver the parent drug into the brain ICF
in vivo. In addition, the distribution of the prodrugs inside the
brain parenchyma can be determined by combining in vivo and
in vitro methods. To further evaluate the potential of this
prodrug approach to enhance the brain uptake of drugs, other
model drugs should be tested. Preferably the model drugs
should have an extremely low in vivo brain uptake. In addition
to evaluating the usefulness of this prodrug approach with
drugs with poor brain uptake, other issues need to be
considered. As the brain uptake of the parent drug is changed
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after the formation of the prodrug, also the distribution in to
other tissues should be evaluated. Although human and rat both
express LAT1 at the BBB, there are differences in the amino acid
sequence of the transporters. Both species share the same LAT1
substrates which is not unreasonable considering the availability
of these amino acids in the diet. However, the ability of both
human and rat LAT1 to recognize the same natural amino acids
does not mean that both LAT1 variations are able to recognize
synthesized amino acids such as amino acid prodrugs.
Therefore, the LAT1 mediated brain uptake of prodrugs in rats
does not necessary mean that these prodrugs are able to utilize
human LAT1. Furthermore, the brain uptake studies in this
thesis, as in majority of other studies, have been made with
healthy animals. However, the BBB is not fully functional in
many CNS disorders. The tight junctions between the
endothelial cells may be compromised and molecules are able to
penetrate the brain more readily. In addition, the expression and
function of influx or efflux transporters may be changed, which
may increase or decrease the brain uptake of the transporter
substrates. Therefore, if possible the brain uptake studies should
also  be  done  with  animals,  which  are  affected  by  the  CNS
disorder that the prodrug is designed to treat.
8.2 SUMMARY OF THE EVALUATION OF GLUCOSE PRODRUGS
Four glucose prodrugs were synthesized and their ability to
cross the BBB via GluT1 was determined for two of the prodrugs
with the in situ rat  brain  perfusion  technique.  These  prodrugs
were D-glucose-ketoprofen ester and D-glucose-indomethacin
ester. Both tested prodrugs demonstrated reversible
concentration dependent inhibition of brain uptake of the
radiotracer [14C]D-glucose in the in situ rat brain perfusion
model, indicating that the prodrugs bind to the GluT1. Both
prodrugs were able to cross the BBB and gain entry into the
brain tissue. In addition, the uptake of the prodrugs was
decreased significantly when 5 °C perfusion medium was used,
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indicating that the uptake was carrier-mediated. Furthermore,
the high polar surface areas of the prodrugs indicate that
passive diffusion across the BBB is limited. The uptake of the
ketoprofen-glucose prodrug was decreased when 50 mM
concentration of D-glucose was added to the perfusion medium.
In addition, the uptake of ketoprofen-glucose prodrug did not
become saturated even at 15 mM concentration, which suggests
that the affinity of the prodrug for GluT1 is low and the capacity
of the transporter is high. It is also possible that the passive
diffusion of ketoprofen-glucose prodrug is significant enough to
obscure the saturation of GluT1-mediated uptake. In the case of
indomethacin-glucose prodrug, the uptake did not decrease
when 50 mM D-glucose was added into the perfusion medium.
However, the unspecific inhibition of GluT1 using lowered
temperature suggests that the uptake of the prodrug is, at least,
partly GluT1-mediated. The lack of inhibition of the prodrug
brain uptake by 50 mM D-glucose indicates that the affinity of
the indomethacin-glucose prodrug for the transporter is much
higher than the affinity of D-glucose or ketoprofen prodrug. This
hypothesis is further supported by the low IC50 value of
indomethacin-glucose prodrug. These results strongly suggest
that a hydrophilic drug can be attached to the hydroxyl group of
D-glucose at the carbon 6-position and still maintain the affinity
of the D-glucose promoiety for the GluT1 transporter. However,
glucose as a promoiety has several limitations. The structure of
glucose  limits  the  amount  of  drug  molecules  to  which
biodegradable bonds can be linked. In essence, only drugs that
bear a carboxyl acid group can be linked without a linker/spacer
with glucose. In addition, the stability of ester prodrugs in the
systemic circulation is not adequate for clinical use if the target
of  the  drugs  resides  in  the  brain.  Therefore  this  prodrug
technology demands further development before being
applicable to in vivo drug delivery.
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8.3 CONCLUSIONS
It is concluded that:
1. It was possible to modify and combine in vitro, in
situ and in vivo methods, in order to evaluate the
mechanism of brain uptake, and the distribution
in the brain parenchyma of developed amino acid
and glucose prodrugs.
2. L-Tyrosine can be conjugated with drug a
molecule with biodegradable linkage to form a
prodrug  that  is  able  to  cross  the  BBB  via  LAT1.
However, the ester bond between ketoprofen and
L-tyrosine is too labile in vivo.
3. Other amino acids than LAT1 substrates such as
L-lysine can be used to form prodrugs that are
LAT1 substrates. This enables the use of different
prodrug bonds between the parent drug and the
amino acid.
4. Amino acid prodrugs can deliver the parent drug
across the BBB and further into the brain ICF in
vivo.
5. D-Glucose can be conjugated with drug molecule
with  biodegradable  linkage  to  form  a  prodrug
that is able to cross the BBB via GluT1. However,
the ester bond between the parent drugs and D-
glucose is too labile in vivo.
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